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 Recent developments in the field of cancer genomics have shown transcription factor 
HIF-1α as a major player in the survival and proliferation of colorectal tumors. Hypoxia targeted 
drug engineering has led to significant advancements in cancer treatments as a method of directly 
utilizing the hypoxic regions against the tumor. Novel drug DCQ (2-benzoyl-3-phenyl 6,7-
dichloroquinoxaline 1,4-dioxide) has shown promising anti-tumor results in-vitro and in-vivo. 
The purpose of this study was to utilize a tumor xenograft and genetic mouse model of colorectal 
cancer to investigate the safety, clinical effectiveness, and mechanism of action of DCQ. 
Methods: 10 week old Balb/c mice were injected subcutaneously with 2 million CT-26 cells and 
were monitored for tumor growth over 14 days before receiving treatment. Apcmin/+ mice were 
clinically evaluated from 8 weeks of age and began treatments at 16 weeks of age. DCQ 
treatment given at a 17mg/kg dose and 100μL DMSO injection as control. Injections were given 
bi-weekly over a four week period. Results: DCQ caused significant decrease in tumor weight 
(p<0.05) and final tumor area (p<0.05) in Balb/c mice at time of sacrifice than control and 
Apcmin/+ mice showed significantly lower clinical score after 1 week of therapy along with 
decreased large tumor size (p<0.05) and number (p<0.05). Histological analysis showed 
increased total apoptotic area (p<0.05) in tumor tissue sections and tumor specific apoptosis in 
colon tissue in both models. Western blot analysis of Balb/c showed a decreased nuclear 
expression of HIF-1α (p<0.05) and increased expression of pro-apoptotic genes 
dephosphorylated-Bad (p<0.001), cleaved caspase-9 (p<0.05), and Bax (p<0.05) paralleled with a 
decrease in anti-apoptotic Bcl-2 gene (p<0.05). Conclusions: DCQ induces tumor specific 
apoptosis through mechanisms involving down regulation of HIF-1α and increased intracellular 
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apoptosis in Balb/c mice and Apcmin/+ mice. Novel drug DCQ may potentially have use as a 
chemotherapeutic agent to reduce the pathology of sporadic intestinal and colorectal cancers. 
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 In 2012 the WHO reported cancer as the leading cause of death worldwide 
accounting for nearly 8.2million deaths. In the United States, cancer related deaths were 
reported as second highest behind heart disease (Torre et al., 2015). Colorectal cancer is 
the second most prevalent cancer in both men and women in the United States in terms of 
incidence and death rates. The American Cancer Society estimates approximately 51,000 
Americans will die of colon cancer and nearly 150,000 new cases will be diagnosed in 
2014 (Siegel, DeSantis, & Jemal, 2014). It is currently estimated that the average 
American has a 5% lifetime risk of developing colorectal cancer and men are at higher 
risk than women are with a morbidity rate of 59 per 100,000 people versus 44 for women. 
The incidence of colorectal cancer increases with advancing age in both genders, with the 
highest risk occurring in those over 69 years of age. The financial burden of colorectal 
cancer has had a large impact on the current health care system. In 2010, the direct cost 
of colorectal cancer was estimated to be $12.2 billion dollars, $10.7 being due to lost 
productivity and premature death (Siegel et al., 2014; Torre et al., 2015). Thus, colorectal 
cancer has had a major impact on both the economy and population of the United States. 
The initial incidence of hypoxia in the tumor environment arises because of 
oxygen diffusion limitations in avascular primary tumors (Lunt, Chaudary, & Hill, 2008; 
Mathonnet et al., 2014; Ryan, Lo, & Johnson, 1998; Zeng, Liu, Pan, Singh, & Wei, 
2014). As a result of increased hypoxia in the tumor environment, the tumor 
microvasculature proliferates and serves to benefit tumor growth and metastasis. Normal 
responses to hypoxia typically see increased microvasculature proliferation in the tissue 
but with eventual compensation by the body through increased red blood cell count and 
increased oxygen carrying capacity of the blood (Lunt et al., 2008; Yasuda, 2008). In the 
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tumor environment, the increased microvasculature proliferation in the tumor tissue is 
highly abnormal and often fails to correct for the oxygen deficit. This persistent hypoxia 
leads to spatial disorganization of the tumor vascular networks and eventually leads to 
intercapillary distances that are beyond the diffusion range of oxygen (~200μm) 
(Brocato, Chervona, & Costa, 2014; Kunz & Ibrahim, 2003).  
 Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that 
plays a critical role in the cellular response to hypoxia. HIF-1 was discovered by the 
identification of a hypoxia response element (HRE; 5′-RCGTG-3′) in the 3′ enhancer of 
the gene for erythropoietin (EPO), a hormone that stimulates erythrocyte proliferation 
and undergoes hypoxia-induced transcription (Semenza, Nejfelt, Chi, & Antonarakis, 
1991). HIF-1 regulates the transcription of a broad range of genes that facilitate responses 
to a hypoxic environment, including genes regulating angiogenesis, erythropoiesis, cell 
cycle, metabolism, and apoptosis. The HIF-1 complex consists of two subunits, HIF-1α 
and HIF-1β, both of which are basic helix-loop-helix proteins of the PAS family. HIF-1α 
in seen to accumulate under hypoxic conditions whereas HIF-1β is constitutively 
expressed in both hypoxic and normoxic conditions. When expressed under hypoxic 
conditions, HIF-1α is seen to play a vital role as a mediator for solid tumor expansion 
including activation of angiogenic factor VEGF. HIF-1β is the Aryl hydrocarbon 
Receptor Nuclear Translocator (ARNT), which is essential for the xenobiotic response 
(Wolff et al., 2013). Under normoxic conditions, undifferentiated HIF-1 is targeted by an 
E3 ubiquitin ligase containing the von Hippel Lindau protein (VLH). The human genome 
contains EGL9 (Egg Laying Nine-9) homologues that are named EGLN1, EGLN2, and 
EGLN3 (also known as PHD2, PHD1, and PHD3 respectively). Prolyl Hydroxilase 
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domain- containing proteins (PHDs) post-translationally modify HIF-1, allowing 
interactions with VHL to occur. All three proteins of PHDs can hydroxylate HIF-1α at 
one of two proline sites within the ODDD (Pro-402 and Pro-564). VHL is part of a larger 
protein complex that includes Elongin-B, Elongin-C, Cul2, RBX1, and a ubiquitin-
conjugating enzyme (E2). This complex, along with ubiquitin-activating enzyme (E1), 
regularly mediates ubiquitylation of HIF-1 and its subunits (Ke & Costa, 2006).  
 In hypoxic conditions, HIF-1α subunits are not recognized by pVHL, this leads to 
accumulation of HIF-1α which dimerize with HIF-1β and translocate into the nucleus. In 
the nucleus, these proteins act as transcriptional regulators with cofactors such as 
CBP/p300 and DNA polymerase II complex to bind to hypoxia-responsive elements 
(HREs) and activate transcription of target genes. The understanding of HIF-1α target 
genes is well understood, HIF-1α-activated genes include Vascular Endothelial Growth 
Factor (VEGF), Glucose Transporter-1 (GLUT1), Lactate Dehydrogenase (LDHA), 
Ertythropoietin (EPO), and Nitric Oxide Synthase (NOS) (He, Jiang, Zhang, & Wu, 
2014; Zeng et al., 2014). 
 Defective apoptosis is frequently associated with malignancies originating from 
B-lymphocytes. Bcl-2 family proteins govern the mitochondrial outer membrane 
permeabilization (MOMP) in the intrinsic regulation of apoptosis. In the presence of a 
trophic factor, PI-3K is activated and leads to the activation of protein kinase B (PKB or 
Akt) which hydrolyzes ATP to phosphorylate pro-apoptotic protein Bcl-2-associated 
death promoter (Bad). Phosphorylated BAD at this point forms a 14-3-3 heterodimer 
which prevents its binding to Bcl-2 which leaves Bcl-2 to form a heterodimer with Bcl-
xL. The formation of this dimer does not allow for the formation and opening of Bax/Bak 
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heterodimer ion channel to promote the release of cytochrome c to the cytoplasm. 
Absence of cytochrome c does not allow for the formation of the cytochrome c/APAF-
1/procaspase-9 multiprotein complex which does not allow for the initiation of apoptosis.  
Therefore, apoptosis is actively inhibited through the blocking of this mechanism which 
is stimulated by the presence of a trophic factor (Erler et al., 2004; Wei et al., 2001; Xin 
& Deng, 2006; Zhang et al., 2004). 
 Quinoxaline di-N-oxides (QdNOs) were approved in the late 1960's for use as 
feed additives in livestock farming to promote animal growth and as an effort to replace 
banned therapeutic antibiotics, penicillin, and tetracyclines (Diab-Assef, Haddadin, 
Yared, Assaad, & Gali-Muhtasib, 2002; Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005). 
Approval of QdNOs for use was due to the large body of evidence showing that 
quinoxaline antibiotics are inhibitors of DNA synthesis and had increased effectiveness 
in anaerobic conditions. The structural design of QdNOs is the key to the increased 
effectiveness of DNA synthesis inhibition in these types of antibiotics. In the presence of 
an electron rich environment, a free radical intermediate is created by the transfer of an 
electron from this electron rich environment to the electron-poor nitrogen centers of the 
1,4-di-N-oxide moiety. In a hypoxic environment, this transfer is more likely to occur due 
to the highly reducing conditions of hypoxic cells, leading to hypoxic cells acting as a 
targeting element to cytotoxicity of these compounds (Diab-Assef, Haddadin, Yared, 
Assaad, & Gali-Muhtasib, 2002; H. U. Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005). 
 Administration of quinoxaline di-N-oxides to tumor cultures has shown promising 
evidence of tumor specific apoptosis and decreased proliferation through interactions 
with the HIF-1α pathway. Preliminary research from the American University of Beirut 
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has shown tumor specific cytotoxicity mechanisms of quinoxaline 1,4-dioxides (QdNOs) 
cultured under hypoxic conditions. The QdNOs were found to possess a 50- to 100- fold 
greater cytotoxicity to human T-84 colorectal cells cultured under hypoxia compared to 
an oxic environment. It was reported that the hypoxia cytotoxicity ratio (HCR), the ratio 
of equitoxic concentrations of the drug under aerobic/anoxic condition, was highly 
structure related and dependent on the nature of the substituents' on the QdNO 
heterocycle. The most cytotoxic, 2-benzoyl-3-phenyl-6,7-dichloro derivative of the 
quinoxaline 1,4-dioxide, or DCQ, was potent at a dose of 1μM with an HCR of 100 and 
significantly reduced the levels of HIF-1α transcript and protein. It was further 
hypothesized that the C-6 and C-7-chlorine of DCQ might play a significant role in the 
selective hypoxic cytotoxicity of the drug (Diab-Assef et al., 2002; H Gali-Muhtasib et 
al., 2000).        
 Administration of DCQ in both tumor cell cultures and healthy epithelial cells at 
concentrations of 5μM and 10μM show promising results to tumor specific induction of 
apoptosis via HIF-1α pathway and up-regulation of pro-apoptotic apoptosis genes (El-
Khatib et al., 2010; H. U. Gali-Muhtasib et al., 2005; Ghattass et al., 2014). While there 
is evidence of direct effectiveness of DCQ in cell cultures and a suggested safe 
concentration of 17mg/kg, there is still an incomplete understanding of the in-vivo 
effectiveness, overall safety, and direct mechanisms of action that account for the tumor 
specific targeting of DCQ. The overall goal of this proposal is to determine clinical 
effectiveness of DCQ in inducing apoptosis of colorectal tumor cells and systemic safety 
of the 17mg/kg dosage in an implant and genetic model of colorectal cancer. Our central 
hypothesis is that DCQ administered at a concentration of 17mg/kg will be effective at 
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reducing tumor size and burden in both models of colorectal cancer and reduce HIF-1α 
expression leading to up-regulated tumor specific mitochondrial induced apoptosis 
without showing signs of systemic toxicity. 
Specific Aim #1 will evaluate the safety and effectiveness of the 17mg/kg DCQ dosage 
in a xenograft and genetic model of colorectal cancer. 
Specific Aim #2: will determine the mechanism of action of DCQ in the two animal 
models of colorectal cancer. 
Working Model: Initially the proposal will examine the overall effectiveness of DCQ on 
decreasing tumor burden and improving animal health of the 17mg/kg dosage in a CT-26 
xenograft model and Apcmin/+model of colorectal cancer (AIM 1). Next, the proposal will 
examine if DCQ therapy works through similar mechanisms in both models to induce 
tumor specific apoptosis (AIM 2). The Apcmin/+ and CT-26 xenograft animal models 
differ in rate of cancer progression and overall clinical tumor burden relative to body 
size, however both serve as effective models of studying colorectal cancer. 
Understanding the effectiveness of DCQ in both a xenograft and genetic model of 
colorectal cancer will serve as an important step for progression of DCQ to human trials 
in addition to furthering our understanding of the role of QdNOs in the prevention and 














Specific Aim #1 will evaluate the safety and effectiveness of the 17mg/kg DCQ 
dosage in a xenograft and genetic model of colorectal cancer. 
 Rationale: It has been previously shown that DCQ is effective in causing tumor 
specific apoptosis and can repress tumor growth in multiple human cancer cell lines 
through activation mechanisms involving down-regulation of HIF-1α pathway (Diab-
Assef et al., 2002; El-Khatib et al., 2010; Ghattass et al., 2014; H. U. Gali-Muhtasib et 
al., 2005; Haykal et al., 2008, 2009). Toxicity studies from the American University of 
Beirut have suggested a concentration of 17mg/kg dose will be effective in causing tumor 
cell apoptosis while staying below systemic toxic levels, therefore preserving essential 
healthy tissue in both the GI system and the entire body. The 17mg/kg dosage has 
previously been shown to be effective in a breast cancer xenograft study, however, there 
is lack of clinical data from this study and DCQ has yet to be investigated in-vivo for 
clinical effectiveness in a colorectal cancer model (Ghattass et al., 2014). Thus, we would 
like to investigate the safety and clinical effectiveness of the 17mg/kg dose in a tumor 
implant and genetic model of colorectal cancer. 
 Aim 1.1: Observation of tumor size and weight in Balb/c mice implanted with 
 CT-26  tumor xenografts over a four week therapy period with DCQ 
 administration at a concentration of 17mg/kg.  
 Aim 1.2: Clinical score of Apcmin/+ mice over a four week therapy period with 
 DCQ administration at a concentration of 17mg/kg.  
 Aim 1.3: Safety of DCQ will be determined by assessment of other vital organs 
 for presence of increased apoptosis and abnormal phenotype 
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Specific Aim #2: will determine the mechanism of action of DCQ in the two animal 
models of colorectal cancer. 
 Rationale: Studies in multiple human cell lines from the American University of 
Beirut have shown consistent results of increased mitochondrial induced apoptosis with 
DCQ treatment. The CT-26 xenograft and Apcmin/+ transgenic mouse are common 
experimental models of colorectal cancer. The mutated Apc gene causes activation of the 
Wnt/β-catenin pathway which is responsible for tumorgenesis in the colon and small 
intestines (Bienz & Clevers, 2000; Leclerc, Deng, Trasler, & Rozen, 2004; Newton, 
Kenneth, Appleton, Näthke, & Rocha, 2010; Näthke & Rocha, 2011). Although this is a 
specific genetic model of cancer there is genetic variability in the tumor formation and 
therefore each tumor site is expected to respond differently to drug treatment. HIF-1α and 
the Apc gene have been shown to have cross-communication at the transcriptional level 
which serves as a driving force for intestinal tumorgenesis (Mehl et al., 2005; Newton et 
al., 2010; Yamulla et al., 2014). Since it has been determined that DCQ works through 
interruption of the HIF-1α pathway, we are interested in mechanistic differences between 
and within the murine CT-26 tumor xenograft model and Apcmin/+ genetic model of 
colorectal cancer. 
 Aim 2.1: Activation of DCQ will be determined through expression of HIF-1α. 
 Decreased HIF-1α will indicate the hypoxic environment of the tumor 
 environment is promoting transformation of DCQ to its active intermediate. 
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 Aim 2.2: Presence of tumor specific apoptosis and expression of pro-apoptotic 
 and anti-apoptotic genes will be performed to compare between the two models of 
 colorectal cancer and indicate mechanisms of mitochondrial induced apoptosis. 
 Aim 2.3: Histological analysis of tumor containing sections of colon and intestine 















































2.1 Colorectal Cancer 
 In 2012 the WHO reported cancer as the leading cause of death worldwide 
accounting for nearly 8.2million deaths. In the United States, cancer related deaths were 
reported as second highest behind heart disease (Torre et al., 2015). Colorectal cancer is 
the second most prevalent cancer in both men and women in the United States in terms of 
incidence and death rates. The American Cancer Society estimates approximately 51,000 
Americans will die of colon cancer and nearly 150,000 new cases will be diagnosed in 
2014 (Siegel et al., 2014). It is currently estimated that the average American has a 5% 
lifetime risk of developing colorectal cancer and men are at higher risk than women are 
with a morbidity rate of 59 per 100,000 people versus 44 for women. The incidence of 
colorectal cancer increases with advancing age in both genders, with the highest risk 
occurring in those over 69 years of age. The financial burden of colorectal cancer has had 
a large impact on the current health care system. In 2010, the direct cost of colorectal 
cancer was estimated to be $12.2 billion dollars, $10.7 being due to lost productivity and 
premature death (Siegel et al., 2014; Torre et al., 2015). Thus, colorectal cancer has had a 
major impact on both the economy and population of the United States. 
Clinical Symptoms of Colorectal Cancer 
 Colorectal cancer is a degenerative disease that takes years to develop in the 
humans. Incidence of colorectal cancer is suggested to be onset by chronic stress and 
poor lifestyle management, the latter of which is typically a lack of physical activity and 
poor diet. In the early stages of the disease, symptoms of colorectal cancer may be 
minimal or not present at all. The quantity and severity of symptoms associated with 
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colorectal cancer typically accompany the progression of the disease. In a clinical setting, 
symptoms of colorectal cancer are broken down into local and systemic. Local symptoms 
are those which have a direct effect on the colon or rectum and are seen in the various 
stages of the disease. These symptoms include changes in bowel habits, constipation, 
diarrhea, alternating diarrhea and constipation, rectal bleeding or bloody stools, 
abdominal bloating or cramping, incomplete bowel emptying, and thinner stools. 
Systemic symptoms are those that effect the entire body and are typically seen in the later 
stages of the disease. These symptoms include unexplained weight loss, unexplained loss 
of appetite, nausea or vomiting, anemia, jaundice, and weakness and fatigue. Due to the 
delayed onset of both local and systemic symptoms past the initial onset of the disease 
regular screening is recommended on a per 5 year basis for everyone over 50 years old.  
2.2 Models of Studying Colorectal Cancer 
 There are many models of studying colorectal cancer that are being utilized to 
understand and investigate development, progression, and potential therapies of the 
condition. Utilization of both genetic and tumor implantation models are common in 
animal research. Cell culture methods have also been utilized, especially for drug 
development, to understand a direct impact of a specific factors and secreted cytokines on 
proliferative and necrotic regulation. Human models are only used in later progressions 
of drug development, therefore many investigators use rodent or in vitro models to study 
treatments and mechanisms involved in colorectal cancer. 
Non-rodent species 
 Canine use has become attractive model for comparative oncology research. 
Similar to rodent models, there are many similarities between canine colorectal cancer 
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and the human disease. One of the benefits to canine intestinal cancer models is the onset 
of tumors is more commonly found in the large intestine rather than the small intestine. 
This more closely mimics the descending colon/rectal cancers that are most frequently 
seen in human onset of the disease (Johnson & Fleet, 2013). Evaluations of canine 
colorectal adenomas have revealed cytoplasmic and nuclear accumulation of β-catenin, 
which further suggests a dysregulation of the WNT signaling pathway is an important 
driver in the onset of colorectal cancer in canine species (McEntee & Brenneman, 1999). 
Despite the similarities between canine and human colorectal cancer, the prevalence in 
canines is less than 1% and therefore severely limits the effectiveness of using this model 
(Johnson & Fleet, 2013; McEntee & Brenneman, 1999).  
 Sheep are also an effective model of studying human colorectal cancer due to the 
similarities of lesions and metastatic behavior between the human disease. Despite this 
similarity, it has been shown that 100% of the intestinal adenocarcinomas developed in 
sheep are found in the small intestine. Along with this limitation, the unique 
physiological characteristics of the sheep ruminant forestomachs has been shown as a 
significant weakness of this model (Johnson & Fleet, 2013; Munday, Brennan, Jaber, & 
Kiupel, 2006). 
CT-26 Adenocarcinoma 
 Another commonly used model is the CT-26 adenocarcinoma model of colorectal 
cancer. CT-26 cells can either be cultured or injected subcutaneously in Balb/c mice, 
which is known as a Xenograft model. Tumors typically develop within 14 days and the 
mice begin to show severe symptoms of tumor burden. While other animal models 
develop multiple intestinal polyps over the course of time, the CT-26 Xenografts develop 
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into large visible tumors that can account for more than 15% of the animal's total body 
weight. This model typically mimics the symptoms of tumor burden which include 
increased circulating IL-6 and insulin resistance (Aulino et al., 2010). Since this model 
typically shows hallmarks of human cancer conditions and allows for rapid studies to be 
conducted, it is often incorporated in preliminary studies for drug and therapy 
development. The accelerated development of the large tumor makes the tumor burden 
less like the human condition, but is still valid as a model of studying colorectal cancer 
(Aulino et al., 2010; Bonetto et al., 2011, 2012).      
Diet-Induced Rodent Neoplasia Models 
 Epidemiological evidence has shown diet as a key modulator to the incidence of 
colorectal cancer in humans (Lee et al., 2012, 2013; Magalhães, Peleteiro, & Lunet, 
2012; Shivappa et al., 2014). Several rodent studies have been conducted to examine the 
influence of poor diet on the incidence of colorectal cancer. This diet typically is 
designed to mimic the poor "Western diet" that has become problematic to the current 
health of many Americans. There are several modifications of a western diet. The 
"Western diet" is designed to increase dietary fat intake from 5% to 20%, decrease 
dietary calcium from 0.5% to 0.05%, and decrease vitamin D intake to 100 IU/kg from 
1,000 IU/kg (Johnson & Fleet, 2013; Newmark, Lipkin, & Maheshwari, 1990). Feeding 
the Western diet for as little as 12 weeks was shown to induce hyperplasia of colonic 
crypts in rats and mice (Newmark et al., 1990). Longevity studies have also shown that 
after 2 years of being fed the Western diet, 70% of the mice developed dysplastic crypts 
and small polypoid lesions, most of which were found in the distal colon (Risio et al., 
1996). Another study has also shown that a 2 year feeding of a Western diet low in fiber, 
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folate, methionine, and choline content lead to 25% of C57BI/6J mice developing 
intestinal tumors and showed lesions demonstrating evidence of adenocarcinoma 
(Johnson & Fleet, 2013; Newmark et al., 2001; Risio et al., 1996). Feeding the Western 
diet to mice has also been shown to induce a transcript profile in normal colonic mucosa 
that was similar to the pattern loss of Apc allele in Apc138N/+ mice (Yang et al., 2008). The 
Western diet model of spontaneous colorectal cancer is an attractive model however the 
changes in physiology seen in many studies do not reflect the etiology of human 
colorectal cancer (Johnson & Fleet, 2013). 
Chemical-Induced Models 
 A large number of chemicals have been shown to have mutagenic potential and 
are used to controllably induce cancer. 1,2-dimethylhydrazine (DMH) and its metabolite 
azoxymethane (AOM), are the two most commonly used carcinogens to induce colorectal 
cancer in rodents (Bissahoyo et al., 2005). DMH and AOM are alkylating agents that are 
typically injected intraperitoneally or subcutaneously over several weeks to induce 
tumorgenesis. The majority of these tumors are seen in the distal colon and are seen to 
harbor mutations in the β-catenin gene. This mutation affects the N-terminal amino acids 
of the β-catenin gene product and leads to resistance of the regulatory degradation, this 
stabilizes β-catenin and increases WNT signaling to drive tumor development (Bienz & 
Clevers, 2000; Komiya & Habas, 2008; Sebio, Kahn, & Lenz, 2014). This model 
therefore is useful for studying the gene-gene and gene-environment interactions that 
influence the pathophysiology of colorectal cancer. However it is suggested that this 
model is not viable due to the little evidence supporting the induction of human colorectal 




 The Apcmin/+ mouse has been one of the leading models for preclinical colorectal 
cancer research over the past 20 years. The phenotype of these mutant mice showed 
severe clinical symptoms of intestinal cancer from the onset of a usually fatal case of 
regenerative anemia attributed to multiple intestinal neoplasms, or "Min." The Min 
mouse has a naturally occurring T-to-A nonsense mutation at nucleotide 2,549 of the 
Adenomatous polyposis coli (Apc) gene that pares the Apc protein at the codon 850, this 
predisposes the mice to multiple intestinal adenomas (Moser, Pitot, & Dove, 1990) . The 
Min mutation is autosomal dominant, and homozygosity for the mutant allele is 
embryonic lethal. Heterozygous Apcmin/+ mice typically become anemic by 60 days of 
age and progress through worsening clinical symptoms of intestinal cancer and usually 
die by 120 days of age (Johnson & Fleet, 2013; Moser et al., 1990).  
 The use of the Apcmin/+ mouse model has been widely used to study 
carcinogenesis or to test a developing treatment and delivery methods, the Apcmin/+ 
mouse has also been used to study genetic modifiers of colorectal cancer risk or 
Modifiers of Min (Mom) (Balmain, Gray, & Ponder, 2003; Johnson & Fleet, 2013). 
2.3 Chemotherapy Treatments 
 Current chemotherapy treatments have undergone a significant improvement in 
tumor cell targeting over the last 60 years. Since the discovery of the DNA replication 
blocking mechanisms of Aminopterin, the predecessor of current treatment methotrexate, 
research into blockading functions of cell growth have been the major focus for the 
development of anti-cancer therapies. As the incidence of different types of cancer was 
evolved in the medical community, there was an increased demand of treatment methods. 
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Present therapies are able to be controlled with early detection and regular 
chemotherapies. As various mechanisms of cancer development and treatment were 
discovered, so paralleled the evolution of chemotherapy treatments. The development of 
chemotherapy treatments have begun to focus on drug combinations, delivery techniques, 
tissue specificity, and overcoming drug resistance by carcinomas (Brown & Wilson, 
2004; McKeown, Cowen, & Williams, 2007; Silvestris et al., 2013).  
 The medical field has seen significant advancements in chemotherapy treatments 
over the last 40 years, however, one of the most common problems in drug design is the 
engineering of compounds to attack specifically the tumor environment and malignant 
tissue sites. Clinically, it is seen that many chemotherapy treatments can improve clinical 
score and wellbeing of the patient but have detrimental effects to healthy tissue. Many of 
the detrimental effects of chemotherapy treatments can be attributed to the non-specific 
targeting of tissue by the drug compound. The toxic effects of these compounds increases 
stress on the body and can ultimately lead to death in the patient (Bai & Wang, 2014; 
Gogvadze, Orrenius, & Zhivotovsky, 2009; Mathonnet et al., 2014; McKeown et al., 
2007; Pettersen et al., 2014; Silvestris et al., 2013).  
Phases of Drug Development  
 The progression of drug testing requires many pre-clinical and clinical steps that 
are highly regulated by the FDA. The first step in drug development is pre-clinical animal 
and in vitro based experiments that show effective and safe delivery methods and propose 
methods for progression to human testing. At this stage, the FDA can decide whether the 
drug is reasonably safe for progression to human trials or to take the drug back to 
formula. Once in clinical trials the drug is considered an investigational new drug and 
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must pass three phases of clinical testing that are overseen by both medical research and 
non-research based scientists and physicians.  
 Phase 1 testing is usually conducted in healthy volunteers in an effort determine 
frequent side effects and how the drug is metabolized and excreted. The typical number 
of subjects for this phase is usually between 20 and 80. Phase 2 studies begin once the 
drug is determined safe for healthy humans and experiments begin to focus on drug 
effectiveness in humans. This phase tests a variety of patients with certain diseases or 
conditions and is compared in a controlled study against a placebo drug or current form 
of treatment. In Phase 2, the number of subjects can be expanded to at most 300 and is 
usually determined based on the range of conditions being investigated. At the end of 
Phase 2, if a drug has shown evidence of effectiveness in a certain population, Phase 3 
can be initiated as a follow-up study with larger subject populations. The number of 
subjects in Phase 3 can be anywhere from a few hundred to 3,000. After passing all three 
phases of human clinical trials, postmarket and commitment studies are required by a 
sponsor and are monitored by the FDA. This typically allows the drug to enter longevity 
studies in humans to determine any long term side effects that may arise from continuous 
use of the drug. Once passed by the FDA the drug can be submitted to the FDA as a new 
drug and within six months the drug can be passed and distributed for use in clinical 
medicine (Kinch, 2014).  
2.4 Hypoxia in the Tumor Microenvironment 
The progression of tumor development in colorectal cancer shows a wide range of 
abnormal physiological characteristics that aide in the maintenance of tumor tissue.  As a 
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solid tumor grows, the rate of cancerous cell proliferation surpasses the ability of the 
existing vasculature to supply growth factors, nutrients, and oxygen and to remove the 
catabolic waste produced by these cells. The result of these events is a change in the 
tumor environment and leads to an imbalance between supply and demand (Cairns, 
Harris, & Mak, 2011; Faubert et al., 2014). Accompanying this change introduces regions 
of hypoxia, low glucose, and low pH (Kunz & Ibrahim, 2003; Lunt et al., 2008; Ryan et 
al., 1998; Zeng et al., 2014). Most solid tumors contain hypoxic or anoxic regions that are 
believed to contribute to local resistance to therapy treatments in addition to promoting 
tumor metastasis. 
Hypoxia  
The initial incidence of hypoxia in the tumor environment arises because of 
oxygen diffusion limitations in avascular primary tumors (Lunt et al., 2008; Mathonnet et 
al., 2014; Ryan et al., 1998; Zeng et al., 2014). As a result of increased hypoxia in the 
tumor environment, the tumor microvasculature proliferates and serves to benefit tumor 
growth and metastasis. Normal responses to hypoxia typically see increased 
microvasculature proliferation in the tissue but with eventual compensation by the body 
through increased red blood cell count and increased oxygen carrying capacity of the 
blood (Lunt et al., 2008; Yasuda, 2008). In the tumor environment, the increased 
microvasculature proliferation in the tumor tissue is highly abnormal and often fails to 
correct for the oxygen deficit. This persistent hypoxia leads to spatial disorganization of 
the tumor vascular networks and eventually leads to intercapillary distances that are 




In the tumor environment, hypoxia has many effects on tumor biology. Many of 
these effects include: selection of genotypes favoring survival under hypoxia-re-
oxygenation injury; pro-survival changes in gene expression that suppress apoptosis and 
support autophagy; and the anabolic switch in central metabolism (Brown, 2007; Lunt et 
al., 2008; Semenza, 2000; Weinmann, Jendrossek, Güner, Goecke, & Belka, 2004). 
Hypoxia also enhances receptor tyrosine kinase-mediated signaling, tumor angiogenesis, 
vasculogenesis, an epithelial-to-mesenchymal transition, invasiveness, metastasis, as well 
as suppressing immune reactivity (Bagnall et al., 2014; Chakraborty, John, & Nag, 2014; 
Dewhirst, 2003; Kaidi, Williams, & Paraskeva, 2007; Li & O’Donoghue, 2008; Vaupel 
& Mayer, 2005). Due to the continuous effects of the hypoxic environment on tumor 
development, hypoxia is implicated in multiple mechanisms in resistance to 
chemotherapy (Zeng et al., 2014; Brocato et al., 2014; Kunz & Ibrahim, 2003; Lunt et al., 
2008; Palazon, Goldrath, Nizet, & Johnson, 2014).  
Hypoxia Inducible Factor-1 
 Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that 
plays a critical role in the cellular response to hypoxia. HIF-1 was discovered by the 
identification of a hypoxia response element (HRE; 5′-RCGTG-3′) in the 3′ enhancer of 
the gene for erythropoietin (EPO), a hormone that stimulates erythrocyte proliferation 
and undergoes hypoxia-induced transcription (Semenza et al., 1991). HIF-1 regulates the 
transcription of a broad range of genes that facilitate responses to a hypoxic environment, 
including genes regulating angiogenesis, erythropoiesis, cell cycle, metabolism, and 
apoptosis. The HIF-1 complex consists of two subunits, HIF-1α and HIF-1β HIF-1, both 
of which are basic helix-loop-helix proteins of the PAS family. HIF-1α in seen to 
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accumulate under hypoxic conditions whereas HIF-1β is constitutively expressed in both 
hypoxic and normoxic conditions. When expressed under hypoxic conditions, HIF-1α is 
seen to play a vital role as a mediator for solid tumor expansion including activation of 
angiogenic factor VEGF. HIF-1β is the Aryl hydrocarbon Receptor Nuclear Translocator 
(ARNT), which is essential for the xenobiotic response (Chai et al., 2014; Unwith, Zhao, 
Hennah, & Ma, 2014; Wolff, Jelkmann, Dunst, & Depping, 2013).  
 Under normoxic conditions, undifferentiated HIF-1 is targeted by an E3 ubiquitin 
ligase containing the von Hippel Lindau protein (VLH). The human genome contains 
EGL9 (Egg Laying Nine-9) homologues that are named EGLN1, EGLN2, and EGLN3 
(also known as PHD2, PHD1, and PHD3 respectively). Prolyl Hydroxylase domain- 
containing proteins (PHDs) post-translationally modify HIF-1, allowing interactions with 
VHL to occur. All three proteins of PHDs can hydroxylate HIF-1α at one of two proline 
sites within the ODD (Pro-402 and Pro-564). VHL is part of a larger protein complex that 
includes Elongin-B, Elongin-C, Cul2, RBX1, and an ubiquitin-conjugating enzyme (E2). 
This complex, along with ubiquitin-activating enzyme (E1), regularly mediates 
ubiquitylation of HIF-1 and its subunits (Ke & Costa, 2006).  
 In hypoxic conditions, HIF-1α subunits are not recognized by pVHL, this leads to 
accumulation of HIF-1α which dimerize with HIF-1β and translocate into the nucleus. In 
the nucleus, these proteins act as transcriptional regulators with cofactors such as 
CBP/p300 and DNA polymerase II complex to bind to hypoxia-responsive elements 
(HREs) and activate transcription of target genes. The understanding of HIF-1α target 
genes is well understood, HIF-1α-activated genes include Vascular Endothelial Growth 
Factor (VEGF), Glucose Transporter-1 (GLUT1), Lactate Dehydrogenase (LDHA), 
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Ertythropoietin (EPO), and Nitric Oxide Synthase (NOS) (He et al., 2014; Zeng et al., 
2014). 
HIF-1α and Tumor Cell Metabolism 
 In a hypoxic environment, the cell relies on anaerobic components of energy 
metabolism to survive. Working at a high rate and with a high power output, the cell 
enhances its anaerobic glucose metabolism pathways, which in turn inhibit mitochondria 
regulation of metabolism. Cytoplasmic presence of undifferentiated HIF-1 and 
differentiated HIF-1α is understood to enhance the activity of glucose transporter 1, 
hexokinase, phosphoglucose isomerase, aldolase, phosphoglycerate kinase, 
phosphoglucomutase, enolase, pyruvate kinase, and lactate dehydrogenase. Essentially, 
the presence of HIFs in the cytoplasm up regulates every enzyme responsible for 
anaerobic metabolism. This increased cellular rate of glycolysis and decreased presence 
and activity of citric acid cycle enzymes is linked with tumor malignancy and can 
contribute to tumor metastasis. This is thought to be especially true of the hypoxic 
regions present in solid tumors. (Cairns et al., 2011; Kaelin, 2011; Pettersen et al., 2014; 
Zeng et al., 2014). A high rate of glucose metabolism is highly regulated in the 
stabilization of HIF-1α which activates transcription of glucose transporters and key 
glycolytic enzymes such as; lactate dehydrogenase A (LDHA), phosphoglycerate kinase-
1 (PGK-1), and hexokinase-1 (HK1). Transcription of these components acts to further 
facilitate the increase in anaerobic glycolysis and the glycolytic switch (Cairns et al., 
2011; Yasuda, 2008; Zeng et al., 2014).  
 In normal tissue, approximately 10% of cellular energy is obtained through 
anaerobic glycoglysis, whereas mitochondrial aerobic respiration accounts for the other 
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90%. In solid tumors, the glycolytic switch increases anaerobic glycolysis contribution to 
more than 50%. However, when tumors are introduced to a normoxic environment 
mitochondrial function does not increase, this mechanism is suggested to be due to 
increased expression of HIF-1α. (Cairns et al., 2011; Racker & Spector, 1981; 
WARBURG, 1956; Zeng et al., 2014). Increased pyruvate dehydrogenase activity 
mediated through HIF-1α facilitates an increased turnover ratio of pyruvate to lactate. 
Furthermore, HIF-1α mediates and increased expression of pyruvate dehydrogenase 
kinase 1 (PDK-1) which functions to block the action of pyruvate dehydrogenase. 
Pyruvate dehydrogenase is responsible for changing pyruvate to acetyl CoA, which is 
then transported to the mitochondria to begin aerobic cellular respiration. Blocking of 
pyruvate dehydrogenase along with increased expression of anaerobic metabolic enzymes 
serves as a two-fold inhibition of aerobic respiration and requires solid tumor to rely 
primarily on glucose metabolism for fuel (Lum et al., 2007) .  HIF-1α is not a simple 
transcription factor inducer of glycolytic genes, but instead reprograms the fate of 
intracellular glucose; this is described as the Warburg effect (Cairns et al., 2011; Kaelin, 
2011; Racker & Spector, 1981; WARBURG, 1956). 
 Growth factor-dependent induction of HIF-1α appears to partially contribute to 
the ability of growth factors and oncogenic mutations to the ability of growth factors and 
oncogenic mutations in the PI3K/Akt signal transduction pathway to induce a metabolic 
conversion to predominantly anaerobic glycolysis (Carmeliet et al., 1998; Lum et al., 
2007; Newton et al., 2010; Palazon, Goldrath, Nizet, & Johnson, 2014). The chronic 
inhibition and low activity of the mitochondria is postulated to results in disruption of 
normal functioning of the mitochondria. The low-oxygen environment in tumor cells can 
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also result in dysregulation of genes involved in normal mitochondrial function, 
especially genes involved in control of apoptosis. Evidence attributes a relationship 
between decreased function of the mitochondria to an over-expressed form of 
mitochondrial-bound hexokinase which also contributes to high rates of glycolysis 
(Faubert et al., 2014; Lum et al., 2007; Mathupala, Ko, & Pedersen, 2009; Sun et al., 
2013; Unwin et al., 2003). A study conducted by Christofk et al., 2008 showed evidence 
of this effect could be due to mutations in the Von Hippel-Lindau tumor suppressor gene, 
the gene responsible for targeting and ubiquitylation of HIF-1. This further suggesting 
HIF-1α may be a key regulator to tumor apoptosis resistance in addition to sustaining 
proliferative stimuli. 
HIF-1α and the Apc gene 
 It is well established that the key response to hypoxia is activation of the 
transcription factor HIF-1α. However, in the tumor microenvironment there is sufficient 
interplay between the HIF-1α regulated gene transcripts and total expression of HIF-1α 
(Carmeliet et al., 1998; Ke & Costa, 2006; Newton et al., 2010; Näthke & Rocha, 2011; 
Palazon, Goldrath, Nizet, & Johnson, 2014). The Apc gene plays a significant role in 
regulation of the fundamental processes that govern normal gut epithelium. It is best 
known for control of the Wnt/β-catenin pathway, where it is responsible for the 
regulation of β-catenin which thereby regulates that transcriptional activity of T-cell 
factor (TCF)/lymphoid-enhancing factor (LEF) transcription factors(Bienz & Clevers, 
2000). 
 Although not extensively investigated, the functional relationship between HIF-1α 
and the Wnt/β-catenin pathway has been established in recent investigations. HIF-1α can 
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specifically interfere with co-activation of TCF/LEF transcription mediated by β-catenin 
and furthermore can bind and regulate NF-κB activity which is theorized to contribute to 
chronic inflammation seen in the colon tissue (Bienz & Clevers, 2000; Kaidi et al., 2007; 
Sebio et al., 2014). Functional cross-talk has also been reported between HIF-1α and the 
Apc gene at the transcriptional level. Newton et al., 2010 reported a consistent direct 
transcriptional repression of Apc by HIF-1α. It was seen that HIF-1α bound to a hypoxia-
responsive element, dubbed HRE, in the APC promoter region in the presence of 
hypoxia. This relationship was also confirmed in an APC depletion model which showed 
an increased HIF-1α expression and activity. The increase of HIF-1α was also determined 
to be mediated by NF-κB and was regulated by increased β-catenin levels which were 
increased due to the depletion of the Apc gene. 
Intracellular induced apoptosis and HIF-1α 
 In the absence of a trophic factor the phosphatidylinositol-4, 5-bisphosphate 3-
kinase (PI-3K)/ protein kinase B (PKB) signaling pathway is not activated and the 
phosphorylation of Bad does not occur. This allows for Bad to bind with anti-apoptotic 
gene B-cell lymphoma 2 (Bcl-2) and prevents the heterodimerization of Bcl-2 with anti-
apoptotic sister gene B-cell lymphoma-extra large (Bcl-xL) on the mitochondrial 
membrane. Absence of this heterodimerization signals for the heterodimerization of Bcl-
2-associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak) on the outer 
mitochondrial membrane which acts as an ion channel and causes an influx of various 
ions across a membrane potential. This ion flux influences the release of cytochrome c 
from the mitochondria into the cytoplasmic space. The release of cytochrome c from the 
mitochondria initiates the formation of multi-protein complex containing cytochrome c, 
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apoptotic protease activating factor 1 (APAF1), and procaspase-9. Formation of this 
complex represents the "point of no return" in the apoptosis pathway and cleaves 
procaspase-9 to form active cleaved caspase-9 which activates the downstream caspase 
cascade and will result in programmed cell death. The release of second mitochondrial-
derived activator of caspases (SMAC), also known as direct inhibitor of apoptosis protein 
(IAP)-binding protein with low pI (DIABLO), is released by the mitochondria to further 
stimulate caspase cascades by inhibiting apoptosis inhibitor proteins (IAPs) (Erler et al., 
2004; Wei et al., 2001; Xin & Deng, 2006; Zhang et al., 2004). 
 Defective apoptosis is frequently associated with malignancies originating from 
B-lymphocytes. Bcl-2 family proteins govern the mitochondrial outer membrane 
permeabilization (MOMP) in the intrinsic regulation of apoptosis. In the presence of a 
trophic factor, PI-3K is activated and leads to the activation of protein kinase B (PKB or 
Akt) which hydrolyzes ATP to phosphorylate pro-apoptotic protein Bcl-2-associated 
death promoter (Bad). Phosphorylated BAD at this point forms a 14-3-3 heterodimer 
which prevents its binding to Bcl-2 which leaves Bcl-2 to form a heterodimer with Bcl-
xL. The formation of this dimer does not allow for the formation and opening of Bax/Bak 
heterodimer ion channel to promote the release of cytochrome c to the cytoplasm. 
Absence of cytochrome c does not allow for the formation of the cytochrome c/APAF-
1/procaspase-9 multiprotein complex which does not allow for the initiation of apoptosis.  
Therefore, apoptosis is actively inhibited through the blocking of this mechanism which 
is stimulated by the presence of a trophic factor (Erler et al., 2004; Moreno-Galindo et al., 
2014; Wei et al., 2001; Xin & Deng, 2006; Zhang et al., 2004). 
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 HIF-1α presents a multi-influential role on the inhibition of intracellular apoptosis 
in the tumor microenvironment. Found on chromosome 14q23.2, HIF-1α is actively 
expressed in a hypoxic environment (Carmeliet et al., 1998; Erler et al., 2004; Kaidi et 
al., 2007; Kunz & Ibrahim, 2003; Poitz et al., 2011; Wolff et al., 2013). Paradoxically, 
cell adaptation to hypoxia leads not only to cell proliferation/survival but also to cell 
death in some circumstances. Hypoxia has been shown to induce apoptosis, where HIF-1 
plays a complex role (Bristow & Hill, 2008; Kaidi et al., 2007; Rouschop et al., 2010; 
Zhou et al., 2014). Genetic studies using embryonic stem cells harboring a deletion of 
HIF-1α have showed decreased apoptosis compared with wild type cells when challenged 
with low oxygen (Carmeliet et al., 1998; Erler et al., 2004). Activation of caspase-3 and 
Apaf-1-mediated caspase-9, and the release of cytochrome c, have been reported in 
several cell types under hypoxic conditions (Favaro, Lord, Harris, & Buffa, 2011; 
McClintock et al., 2002; Pettersen et al., 2014; Rouschop et al., 2010). It has also been 
demonstrated that the expression of HIF-1α and HIF-1β significantly correlated with 
apoptosis and the pro-apoptotic factors, such as caspase-3, Fas, and Fas ligand (Volm & 
Koomägi, 2000). Furthermore, hypoxia depresses anti-apoptotic protein Bcl-2, whereas 
the pro-apoptotic protein Bcl-2/adenovirus EIB 19-kDa interacting protein 3 (BNip3) and 
its homolog Nip3-like protein X (NIX) were up-regulated in a HIF-dependent manner 
(Bruick, 2000; Kunz & Ibrahim, 2003). Some genes involved in cell cycle control, such 
as p53 and p21, were also found to be HIF-dependent (Carmeliet et al., 1998; Diab-Assef 
et al., 2002; Erler et al., 2004). In addition, p53 has been implicated in regulating 
hypoxia-induced apoptosis through induction of apoptosis-related genes such as Bax, 
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NOXA, PUMA, and PERP (Bai & Wang, 2014; Kunz & Ibrahim, 2003; Rosado-Berrios, 
Vélez, & Zayas, 2011; Weinmann et al., 2004). 
 In addition to the above classes of genes, HIF-1 also regulated many other target 
genes implicated in diverse processes such as adipogenesis (Lin, Lee, Shim, Chun, & 
Yun, 2010; Yun, Maecker, Johnson, & Giaccia, 2002), carotid body formation (Favaro et 
al., 2011; Kline, Peng, Manalo, Semenza, & Prabhakar, 2002), B lymphocyte 
development, and immune reactions (El Awad et al., 2000; Hellwig-Bürgel, Rutkowski, 
Metzen, Fandrey, & Jelkmann, 1999; Rosado-Berrios et al., 2011). Although there are 
some studies showing a role of HIF-2α in the VEGF induction (Duan, Zhang-Benoit, & 
Fong, 2005; Xue & Shah, 2013; Xue et al., 2012), no direct target genes have yet been 
identified for HIF-2α or HIF-3α. However, a recent study using a genetic “knock-in” 
strategy has shown that targeted replacement of HIF-1α with HIF-2α results in expanded 
expression of HIF-2α-specific target genes, the most significant find being Oct-4, a 
transcription factor essential for maintaining stem cell pluripotency (Covello et al., 2006). 
2.5 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide  
 Quinoxaline di-N-oxides (QdNOs) were approved in the late 1960's for use as 
feed additives in livestock farming to promote animal growth and as an effort to replace 
banned therapeutic antibiotics, penicillin, and tetracyclines (Diab-Assef et al., 2002; H. 
U. Gali-Muhtasib et al., 2005). Approval of QdNOs for use was due to the large body of 
evidence showing that quinoxaline antibiotics are inhibitors of DNA synthesis and had 
increased effectiveness in anaerobic conditions. The structural design of QdNOs is the 
key to the increased effectiveness of DNA synthesis inhibition in these types of 
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antibiotics. In the presence of an electron rich environment, a free radical intermediate is 
created by the transfer of an electron from this electron rich environment to the electron-
poor nitrogen centers of the 1,4-di-N-oxide moiety. In a hypoxic environment, this 
transfer is more likely to occur due to the highly reducing conditions of hypoxic cells, 
leading to hypoxic cells acting as a targeting element to cytotoxicity of these compounds 
(Diab-Assef et al., 2002; El-Khatib et al., 2010; H Gali-Muhtasib et al., 2000; H. U. Gali-
Muhtasib et al., 2005; Hala Gali-Muhtasib et al., 2004; Ganley et al., 2001). 
 
Figure 2.1 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide. 
 
 DCQ administration has shown promising evidence of tumor specific apoptosis 
and decreased proliferation through interactions with the HIF-1α pathway. Preliminary 
research from the American University of Beirut has shown tumor specific cytotoxicity 
mechanisms of quinoxaline 1,4-dioxides (QdNOs) cultured under hypoxic conditions. 
The QdNOs were found to possess a 50- to 100- fold greater cytotoxicity to human T-84 
colorectal cells cultured under hypoxia compared to an oxic environment. It was reported 
that the hypoxia cytotoxicity ratio (HCR), the ratio of equitoxic concentrations of the 
drug under aerobic/anoxic condition, was highly structure related and dependent on the 
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nature of the substituents' on the QdNO heterocycle. The most cytotoxic, 2-benzoyl-3-
phenyl-6,7-dichloro derivative of the quinoxaline 1,4-dioxide was potent at a dose of 
1μM with an HCR of 100 and significantly reduced the levels of HIF-1α transcript and 
protein. It was further hypothesized that the C-6 and C-7-chlorine of DCQ might play a 
significant role in the selective hypoxic cytotoxicity of the drug (Diab-Assef et al., 2002; 
H Gali-Muhtasib et al., 2000).      
 In a supplemental study, DCQ was tested for IC50 and compared to QdNOs; AMQ 
and BPQ. It was seen that the IC50 of AMQ, BPQ, and DCQ were 100, 20, and 1μM, 
respectively. Thus, the concentration of DCQ to induce 50% growth inhibition was 20-
fold lower than that of BPQ and 100-fold lower than that of AMQ. It was also seen that 
these compounds were not cytotoxic to normal intestinal IEC-6 or Moe K cells at their 
IC50 concentration (Diab-Assef et al., 2002; H. U. Gali-Muhtasib et al., 2005). To 
investigate the effect of DCQ on tumor cells, H. U. Gali-Muhtasib et al., 2005 exposed 
cultured T-84 human colon carcinoma cells to 1μM DCQ for a 48 hour period. Upon 
treatment with DCQ, the accumulation of sub-G1 peak of hypo-diploid cells was evident 
and was seen in more than 35% of total cells. TUNEL assay of cultured cells also showed 
60% of cultured cells were positive for dsDNA strand breaks compared to 35% for BPQ 
and 10% for AMQ. These findings suggested DCQ works by targeting the tumor 
microenvironment to induce anti-proliferative effects specifically in the tumor cells 
through an increase in cell apoptosis pathways (Diab-Assef et al., 2002; H. U. Gali-
Muhtasib et al., 2005). It was also seen that DCQ significantly increased pro-apoptotic 
protein Bax and decreased anti-apoptotic protein Bcl-2 in T-84 cells. This indicating 
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activation of mitochondrial induced apoptosis of the cell as a specific mechanism of 
action leading to tumor cell apoptosis. 
 DNA damage, in particular dsDNA breaks, imposes a threat to the survival of 
cells if left unrepaired. At the early stages of the DNA damage response, Ataxia 
telangiectasia mutated kinase (ATM) is autophosphorylated on Ser1981 as a response to 
the presence of dsDNA breaks. ATM activation, in turn, proceeds to phosphorylate p53, 
thereby blocking its interaction with E3 ubiquitin-protein ligase (MDM2), causing its 
stabilization. Stabilized p53 stimulates the expression of cyclin-dependent kinase 
inhibitor p21. Through its various interactions, p21 inhibits G1/S and G2/M transitions 
which lead to cell cycle arrest and repair or apoptosis. Thus, increased expression of p53 
levels that are paralleled by increased p-ATM and p21 are due to this pathway activation 
and lead to cell-cycle arrest, repair, and cell death. Malignant tumor cells harbor a 
defective p53 and are resistant to this pathway, this favors their clonal outgrowth and 
contributes to the resistance of normal cell cycle responses to DNA damage, a cause of 
chemotherapy and radiation resistance (Kaluzová, Kaluz, Lerman, & Stanbridge, 2004; 
Lakin & Jackson, 1999; Vilenchik & Knudson, 2003).  
 In an attempt to investigate the specific cytotoxic mechanisms of DCQ, El-Khatib 
et al., 2010 treated cultured HCT116 (p53+/+), HCT116 (p53-/-), and HCT116 (p21-/-) cells 
to 0, 5, and 10μM DCQ in DMSO media for 6, 12, and 24 hours under normoxic and 
hypoxic conditions. p53 protein increased in response to DCQ in all three cell lines with 
the exception of the p53+/+ cells exposed to hypoxia, the same pattern was also seen for 
p21 protein expression. Caspase-2 expression was increased in p53+/+ cells and was 
further increased by 8-10 fold under hypoxia. In p53-/- showed no increase in caspase-2 
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and a decreased expression was seen in p21-/- cells. Although no direct interaction 
between p53 and caspase-2 has been observed, it is theorized that a functional connection 
between these two proteins is essential for the initiation of drug-induced apoptosis (Erler 
et al., 2004; Lakin & Jackson, 1999; Seth, Yang, Kaushal, Shah, & Kaushal, 2005). 
Overall, the apoptotic effects of DCQ in p53+/+ cells correlated with an increase in the 
pro-apoptotic caspase-2 protein, inhibition of pro-survival protein p53-induced protein 
with a death domain (PIDD-C), and increase in p-ATM expression. 
 The p21 gene is transcriptionally activated by p53 and is responsible for the p53-
dependent checkpoint which induces cell cycle arrest in the event of DNA damage. 
Enforced p21 expression is known to result in a consistent, but partial, protection of cells 
from apoptosis (Bunz et al., 1998; Kaluzová et al., 2004; Lakin & Jackson, 1999; et al., 
2005). A significant increase was observed in both p53+/+ and p53-/- cells when treated 
with DCQ in a hypoxic environment, this suggesting that p21 activation is independent of 
p53 in the case of DCQ. The decrease in the expression of pro-survival PIDD-C protein 
coupled with the increase in pro-apoptotic caspase-2 in p53+/+ cells appeared to have 
committed the cells to apoptosis. Interestingly, in p53-/- and p21-/- cells, apoptotic cell 
death occurred independent of caspase-2 activation and/or PIDD-C down-regulation (El-
Khatib et al., 2010). This suggesting that the apoptotic mechanism involved in the tumor 
selective cell death of DCQ is independent of p53 and p21 proteins, further suggesting 
the involvement of other apoptotic mechanisms.  
 Administration of DCQ in both tumor cell cultures and healthy epithelial cells at 
concentrations of 5μM and 10μM show promising results to tumor specific induction of 
apoptosis via HIF-1α pathway and intracellular apoptosis (El-Khatib et al., 2010; H. U. 
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Gali-Muhtasib et al., 2005; Ghattass et al., 2014). While there is evidence of direct 
effectiveness of DCQ in cell cultures and a suggested safe concentration of 17mg/kg 
dosage, there is still an incomplete understanding of the effectiveness, safety, and direct 
mechanisms of action that account for the tumor specific targeting of DCQ. The overall 
goal of this proposal is to determine clinical effectiveness of DCQ in inducing apoptosis 
of colorectal tumor cells and systemic safety of the 17mg/kg dosage in an implant and 
genetic model of colorectal cancer. Our central hypothesis is that DCQ administered at a 
concentration of 17mg/kg will be effective at reducing tumor size and burden in both 
models of colorectal cancer and continue to work through the HIF-1α pathway and 
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Recent developments in the field of cancer genomics have shown transcription factor 
HIF-1α as a major player in the survival and proliferation of colorectal tumors. Presence 
of hypoxic areas in tumors facilitate the differentiation and nuclear translocation of HIF-
1α which leads to transcription of hypoxic genes causing vascularization and metastasis 
of tumors. Hypoxia targeted drug engineering has led to significant advancements in 
cancer treatments as a method of directly utilizing the hypoxic regions against the tumor. 
Novel drug DCQ (2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide) has shown 
promising anti-tumor results in-vitro and in-vivo. The purpose of this study was to utilize 
a tumor xenograft and genetic mouse model of colorectal cancer to investigate the safety, 
clinical effectiveness, and mechanism of action of DCQ. Methods: 10 week old Balb/c 
mice were injected subcutaneously with 2 million CT-26 cells and were monitored for 
tumor growth over 14 days before receiving treatment. Apcmin/+ mice were clinically 
evaluated from 8 weeks of age and began treatments at 16 weeks of age. DCQ treatment 
given at a 17mg/kg dose and 100μL DMSO injection as control. Injections were given bi-
weekly over a four week period. At sacrifice, all tissues were extracted for histological 
and protein analysis. Results: DCQ caused significant decrease in tumor weight (p<0.05) 
and final tumor area (p<0.05) in Balb/c mice at time of sacrifice than control. Apcmin/+ 
mice showed significantly lower clinical score after 1 week of therapy along with 
decreased large tumor size (p<0.05) and number (p<0.05). Histological analysis showed 
increased total apoptotic area (p<0.05) in tumor tissue sections and tumor specific 
apoptosis in colon tissue in both models. Western blot analysis of Balb/c tumors and 
Apcmin/+ colon tumors showed a decreased nuclear expression of HIF-1α (p<0.05) and 
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increased expression of pro-apoptotic genes dephosphorylated-Bad (p<0.001), cleaved 
caspase-9 (p<0.05), and Bax (p<0.05) paralleled with a decrease in anti-apoptotic Bcl-2 
gene (p<0.05). Conclusions: DCQ induces tumor apoptosis involving down regulation of 
HIF-1α and increased intracellular apoptosis in Balb/c mice and Apcmin/+ mice. Novel 
drug DCQ may potentially have use as a chemotherapeutic agent to reduce the pathology 
of sporadic intestinal and colorectal cancers. 
















In 2012 the WHO reported cancer as the leading cause of death worldwide 
accounting for nearly 8.2 million deaths. In the United States, cancer related deaths were 
reported as second highest behind heart disease (Torre et al., 2015). Colorectal cancer is 
the second most prevalent cancer in both men and women in the United States in terms of 
incidence and death rates. The American Cancer Society estimates approximately 51,000 
Americans will die of colon cancer and nearly 150,000 new cases will be diagnosed in 
2014 (Siegel, DeSantis, & Jemal, 2014). The financial burden of colorectal cancer has 
had a large impact on the current health care system. In 2010, the direct cost of colorectal 
cancer was estimated to be $12.2 billion dollars, $10.7 being due to lost productivity and 
premature death (Siegel et al., 2014; Torre et al., 2015). Thus, a need does exist for the 
development of safer and more effective therapeutic treatments in order to prevent loss of 
life from ineffective treatments.  
The initial incidence of hypoxia in the tumor environment arises because of 
oxygen diffusion limitations in avascular primary tumors (Lunt, Chaudary, & Hill, 2008; 
Mathonnet et al., 2014; Ryan, Lo, & Johnson, 1998; Zeng, Liu, Pan, Singh, & Wei, 
2014). As a result of increased hypoxia in the tumor environment, the tumor 
microvasculature proliferates and serves to benefit tumor growth and metastasis. Normal 
responses to hypoxia typically see increased microvasculature proliferation in the tissue 
but with eventual compensation by the body through increased red blood cell count and 
increased oxygen carrying capacity of the blood (Lunt et al., 2008; Yasuda, 2008). In the 
tumor environment, the increased microvasculature proliferation in the tumor tissue is 
highly abnormal and often fails to correct for the oxygen deficit. This persistent hypoxia 
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leads to spatial disorganization of the tumor vascular networks and eventually leads to 
intercapillary distances that are beyond the diffusion range of oxygen (~200μm) 
(Brocato, Chervona, & Costa, 2014; Kunz & Ibrahim, 2003).  
 Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that 
plays a critical role in the cellular response to hypoxia. HIF-1 was discovered by the 
identification of a hypoxia response element (HRE; 5′-RCGTG-3′) in the 3′ enhancer of 
the gene for erythropoietin (EPO), a hormone that stimulates erythrocyte proliferation 
and undergoes hypoxia-induced transcription (Semenza, Nejfelt, Chi, & Antonarakis, 
1991). HIF-1 regulates the transcription of a broad range of genes that facilitate responses 
to a hypoxic environment, including genes regulating angiogenesis, erythropoiesis, cell 
cycle, metabolism, and apoptosis. The HIF-1 complex consists of two subunits, HIF-1α 
and HIF-1β, both of which are basic helix-loop-helix proteins of the PAS family. HIF-1α 
is thought to accumulate under hypoxic conditions whereas HIF-1β is constitutively 
expressed in both hypoxic and normoxic conditions. When expressed under hypoxic 
conditions, HIF-1α plays a vital role as a mediator for solid tumor expansion including 
activation of angiogenic factor VEGF. HIF-1β is the Aryl hydrocarbon Receptor Nuclear 
Translocator (ARNT), which is essential for the xenobiotic response (Wolff et al., 2013). 
Under normoxic conditions, undifferentiated HIF-1 is targeted by an E3 ubiquitin ligase 
containing the von Hippel Lindau protein (VLH). The human genome contains EGL9 
(Egg Laying Nine-9) homologues that are named EGLN1, EGLN2, and EGLN3 (also 
known as PHD2, PHD1, and PHD3 respectively). Prolyl Hydroxilase domain- containing 
proteins (PHDs) post-translationally modify HIF-1, allowing interactions with VHL to 
occur. All three proteins of PHDs can hydroxylate HIF-1α at one of two proline sites 
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within the ODD (Pro-402 and Pro-564). VHL is part of a larger protein complex that 
includes Elongin-B, Elongin-C, Cul2, RBX1, and an ubiquitin-conjugating enzyme (E2). 
This complex, along with ubiquitin-activating enzyme (E1), regularly mediates 
ubiquitylation of HIF-1 and its subunits (Ke & Costa, 2006).  
 In hypoxic conditions, HIF-1α subunits are not recognized by pVHL, this 
condition leads to accumulation of HIF-1α which dimerize with HIF-1β and translocate 
into the nucleus. These proteins in the nucleus act as transcriptional regulators with 
cofactors such as CBP/p300 and DNA polymerase II complex to bind to hypoxia-
responsive elements (HREs) and activate transcription of target genes. The functioning of 
HIF-1α target genes is well understood. HIF-1α-activated genes include Vascular 
Endothelial Growth Factor (VEGF), Glucose Transporter-1 (GLUT1), Lactate 
Dehydrogenase (LDHA), Ertythropoietin (EPO), and Nitric Oxide Synthase (NOS) (He, 
Jiang, Zhang, & Wu, 2014; Zeng et al., 2014). Although not extensively investigated, the 
functional relationship between HIF-1α and the Wnt/β-catenin pathway has been 
established in recent investigations. HIF-1α can specifically interfere with co-activation 
of TCF/LEF transcription mediated by β-catenin and furthermore can bind and regulate 
NF-κB activity which is theorized to contribute to chronic inflammation seen in the colon 
tissue (Bienz & Clevers, 2000; Kaidi et al., 2007; Sebio et al., 2014). Functional cross-
talk has also been reported between HIF-1α and the Apc gene at the transcriptional level. 
Newton et al., 2010 reported a consistent direct transcriptional repression of Apc by HIF-
1α. It was seen that HIF-1α bound to a hypoxia-responsive element, dubbed HRE, in the 
APC promoter region in the presence of hypoxia. This relationship was also confirmed in 
an APC depletion model which showed an increased HIF-1α expression and activity. The 
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increase of HIF-1α was also determined to be mediated by NF-κB and was regulated by 
increased β-catenin levels which were increased due to the depletion of the Apc gene. 
 Quinoxaline di-N-oxides (QdNOs) were approved in the late 1960's for use as 
feed additives in livestock farming to promote animal growth and as an effort to replace 
banned therapeutic antibiotics, penicillin, and tetracyclines (Diab-Assef, Haddadin, 
Yared, Assaad, & Gali-Muhtasib, 2002; Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005). 
Approval of QdNOs for use was due to the large body of evidence showing that 
quinoxaline antibiotics are inhibitors of DNA synthesis and had increased effectiveness 
in anaerobic conditions. The structural design of QdNOs is the key to the increased 
effectiveness of DNA synthesis inhibition in these types of antibiotics. In the presence of 
an electron rich environment, a free radical intermediate is created by the transfer of an 
electron from this electron rich environment to the electron-poor nitrogen centers of the 
1,4-di-N-oxide moiety. In a hypoxic environment, this transfer is more likely to occur due 
to the highly reducing conditions of hypoxic cells, leading to hypoxic cells acting as a 
targeting element to cytotoxicity of these compounds (Diab-Assef, Haddadin, Yared, 
Assaad, & Gali-Muhtasib, 2002; H. U. Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005). 
 Administration of quinoxaline di-N-oxides to tumor cultures has shown promising 
evidence of tumor specific apoptosis and decreased proliferation through interactions 
with the HIF-1α pathway. Preliminary research from the American University of Beirut 
has shown tumor specific cytotoxicity mechanisms of quinoxaline 1,4-dioxides (QdNOs) 
cultured under hypoxic conditions. The QdNOs were found to possess a 50- to 100- fold 
greater cytotoxicity to human T-84 colorectal cells cultured under hypoxia compared to 
an oxic environment. Diab-Assef et. al., 2002 reported that the hypoxia cytotoxicity ratio 
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(HCR), the ratio of equitoxic concentrations of the drug under aerobic/anoxic condition, 
was highly structure related and dependent on the nature of the substituents' on the QdNO 
heterocycle. The most cytotoxic, 2-benzoyl-3-phenyl-6,7-dichloro derivative of the 
quinoxaline 1,4-dioxide, or DCQ, was potent at a dose of 1μM with an HCR of 100 and 
significantly reduced the levels of HIF-1α transcript and protein. Others have further 
hypothesized that the C-6 and C-7-chlorine of DCQ might play a significant role in the 
selective hypoxic cytotoxicity of the drug (Diab-Assef et al., 2002; H Gali-Muhtasib et 
al., 2000). While there is evidence of direct effectiveness of DCQ in cell cultures and a 
suggested maximal tolerated dose of 17 mg/kg, incomplete understanding of the in-vivo 
effectiveness still exist, as does the overall safety, and direct mechanisms of action that 
account for the tumor specific targeting of DCQ. The goal of this study is to determine 
clinical effectiveness of DCQ in inducing apoptosis of colorectal tumor cells and 
systemic safety of the 17 mg/kg dosage in a xenograft and genetic model of colorectal 
cancer. We hypothesized that DCQ administered at a concentration of 17 mg/kg is 
effective at reducing tumor burden in both models of colorectal cancer and reduce HIF-
1α expression along with up-regulated tumor specific intracellular induced apoptosis 
without showing signs of healthy tissue toxicity. 
3.3 Methods 
Animals 
 Sixteen female Balb/c mice and ten Apcmin/+ mice were bred and housed at the 
Arnold School of Public Health animal facility at the University of South Carolina. Mice 
were grouped housed, given access to food and water ad libitum, and kept on a 12-hour 
light-dark cycle. The study was approved by the Institutional Animal Care and Use 
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Committee at the University of South Carolina and was carried out in compliance with 
the Guide for Care and Use of Laboratory Animals (National Institutes of Health, 
Bethesda, MD). The study used two separate animal models to investigate both an 
implant model of colorectal cancer and a genetic model of sporadic intestinal and 
colorectal cancer. DCQ treatment was designed to model an intense cycle of single agent 
chemotherapy at a progressed stage of colorectal cancer.  
Experimental Design: Balb/c Xenograft mice 
 The study designed did incorporate two separate animal models to investigate 
both an implant model of colorectal cancer and a genetic model of sporadic intestinal and 
colorectal cancer. At 10 weeks of age, Balb/c mice were randomly assigned (n=8/group) 
to a DMSO control group or a DCQ treatment group. Mice in each group were injected 
sub-dermally (s.d.) with 2 x 106 CT-26 cells into the subcutaneous area of the right flank, 
in incomplete media, and allowed tumors to grow for 2 weeks before receiving 4 weeks 
of bi-weekly treatments (Figure 1A). Mice weight was determined daily, and the date of 
death was recorded. Changes in tumor size were monitored bi-weekly by measurement of 
tumor size (length and width) with a caliper device.  
Experimental Design: Apcmin/+ mice 
At 8 weeks of age, Apcmin/+ mice were assigned (n=5/group) to a DMSO control 
group or a DCQ treatment group and began receiving treatments at 16 weeks of age. 
Mice were given DCQ at a 17 mg/kg dosage dissolved in 100 μL DMSO as a treatment 
or 100 μL DMSO as control which were administered intraperitoneally (i.p.), twice per 
week for 4 weeks (Figure 1B). Toxicity studies by the American University of Beirut 
have shown that 17 mg/kg in 100 μL DMSO is a tolerated dosage based on mice behavior 
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and body weight. Clinical score was kept for Apcmin/+ mice from 8 weeks of age through 
20 weeks of age, and clinical scores were determined based on the predetermined 
guidelines of the Integrated Immunology of Inflammation and Cancer lab (Table 1). 
Tissue Collection 
 Balb/c mice treated with DMSO or DCQ were sacrificed after 4 weeks of therapy. 
Apcmin/+ mice treated with DMSO were sacrificed after 4 weeks of therapy as well. 
Apcmin/+ mice treated with DCQ were sacrificed after 5 weeks of therapy due to 
continually improved health. At the time of sacrifice, mice were first injected with 1mg 
of Bromodeoxyuridine (BrdU) dissolved in sterile PBS, mice then underwent DEXA scan 
and were anesthetized 2 hours (hr) later with an isofluorane-oxygen gas mixture and 
sacrificed by cervical dislocation. The colon was removed and flushed with PBS 
containing 5000 IU/mL and 5000 IU/mL penicillin and streptomycin (CELLGRO), 
respectively. From Apcmin/+ mice, two 2 mm2 sections of the descending colon were 
dissected and stored at −80°C for Western blot analysis and at 37 °C, 5% CO2 with 
overnight incubation for tissue culture. A single tumor containing section of colon was 
fixed in 10% formalin (AZER SCIENTIFIC) for a day then embedded in paraffin wax for 
immunohistochemistry staining. Remaining sections of all tissues were snap-frozen in 
dry ice, and stored in -80 0C until further analysis (Saxena et al., 2014). Tissues analyzed 
for HIF-1α, especially tumor xenografts, were excised and frozen or stored in formalin, in 
under 1minute (min) due to the rapid degradation of HIF-1α in a normoxic environment 





Tumor quantification.  
Formalin-fixed intestinal sections from all animals were rinsed in deionized 
water, briefly stained in 0.1 % methylene blue, and counted by the same investigator who 
was blinded to the treatments. Tumors were counted under a dissecting microscope and 
were categorized according to size (>2 mm, 1–2 mm, and <1 mm).  
Western Blot Analysis 
 Briefly, tumor xenografts, small intestine tumors, and colon tumors were 
homogenized using the Nuclear extraction kit (ab113474) from Abnova to separate 
cytoplasmic and nuclear proteins. Protein concentration was determined by the Bradford 
method (Bradford, 1976). Crude homogenates (10-50μg) were separated on 10-15 % 
polyacrylamide gels by SDS-PAGE gel electrophoresis. Gels were transferred to 
nitrocellulose membranes in cold transfer buffer over a 3 hour period. Equal protein 
loading of the gels was assessed by ponceau staining. Membranes were then blocked in 5 
% milk-PBST for one hour at room temperature. Primary antibodies for Hypoxia 
Inducible Factor-1α (HIF-1α; Abnova) in the nucleus, and cytoplasmic cleaved caspase-
9, dephosphorylated-Bad (d-Bad), Bax, and Bcl-2 were incubated at 1:500 to 1:1000 
dilutions in 5 % milk-PBST overnight at 4 0C. HIF-1α was incubated for 2.5 hours at 
room temperature. Secondary anti-rabbit IgG conjugated antibodies were incubated with 
membranes at a 1:2000 dilution in 5 % milk-PBST for 75 (min) at room temperature. All 
antibodies were purchased from cell signaling unless otherwise stated. Enhanced 
chemiluminescence was used to visualize the antibody-antigen interaction and developed 
by the SYNGENE G:BOX Chemi XX6. Digitally developed blots were analyzed by 
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measuring the integrated optical density (IOD) of each band using digital imaging 
software (GeneTools from Syngene, Cambridge, UK). 
Colon Histopathology  
 To analyze colon histopathology, tumor containing sections of the descending 
colon were stained with hematoxylin and eosin stains. Tumor containing sections of the 
descending colon represent advanced stage tumors (Saxena et al., 2014). Briefly, tissues 
were sectioned at 5μm thickness and deparaffinized by standard procedure using xylene 
and gradation of ethanol. Sections were then washed for 5 min in dH2O, stained with 
filtered hematoxylin for 5min, then again washed 6x5 min in dH2O. Sections were 
washed in acid alcohol mix (160 mL 100 % EtOH, 1 mL acetic acid, and volumed to 200 
mL with dH2O) for 6 dips then again washed in dH2O for 4 dips. Sections were then 
washed in Ammonia H2O (0.6 mL Ammonium OH volumed to 200 mL with dH2O) for 6 
dips and then again washed in dH2O for 10 min. The sections were then stained with 
Eosin for 3min and dehydrated in the following alcohol progression; 1x2 min 70 % 
EtOH, 1x2 min 95 % EtOH, 2x3 min 100 % EtOH, and 2x5 min xylene. Slides were then 
air dried overnight and mounted for viewing with mounting media. Digital photographs 
were taken from each section at a 40x and 20x magnification with a Nikon E600 
Widefield Epifluorescence and Darkfield Microscopy System at the University of South 
Carolina School of Medicine.  
Apoptosis Detection by TUNEL Assay 
 Terminal deoxynucleaotidyl transferase (TdT)-mediated dUTP-biotin nick-end 
labeling (TUNEL) technique was used as per manufacturer instruction (R&D systems) to 
detect DNA strand breaks in situ. Briefly, tumor xenografts from Balb/c mice and colon 
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tumors from Apcmin/+ mice were sectioned at 5 μm thickness and deparaffinized by 
standard procedure using xylene and gradation of ethanol. Negative controls were 
performed by substituting PBS for TdT enzyme, which exhibited no immunostaining. 
Enumeration of apoptotic nuclei was made on slides of sections from each mouse using a 
digital photographs taken at 4x and 20x magnification with a Nikon E600 Widefield 
Epifluorescence and Darkfield Microscopy System at the University of South Carolina 
School of Medicine. All nuclei counted showing a brown labeling. The incidence of 
apoptotic nuclei was given a percentage of total area of entire tumors in tumor xenografts 
(total apoptotic area) and counted within the tumor in the case of colon tumors from 
Apcmin/+ mice. Staining was performed in three separate experiments and counting was 
performed by the same investigator who was blinded to the treatments. Reliability of 
counting was obtained by calculating the coefficient of variance between each of the 
three data sets and was determined to be less than 10%. 
Cell Proliferation by BrdU Assay 
 Immunohistochemistry was performed to detect proliferating cells marked with 
Bromodeoxyuridine by BrdU IN-SITU Detection Kit from BD Pharmingen (550803). 
Briefly, tumor xenografts from Balb/c mice and colon tumors from Apcmin/+ mice were 
sectioned at 5μm thickness and deparaffinized by standard procedure using xylene and 
gradation of ethanol. Negative controls were performed by substituting PBS for anti-
BrdU primary antibody incubation, which exhibited no immunostaining. Enumeration of 
positively marked cells was made on slides of sections from each mouse using digital 
photographs taken at 4x and 20x magnification with a Nikon E600 Widefield 
Epifluorescence and Darkfield Microscopy System at the University of South Carolina 
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School of Medicine. Positive cells were indicated by a brown labeling. The incidence of 
proliferating cells was given a percentage of total area of entire tumors in tumor 
xenografts (total proliferative area) and counted in the case of colon tumors. Staining was 
performed in three separate experiments and counting was performed by the same 
investigator who was blinded to the treatments. Reliability of counting was obtained by 
calculating the coefficient of variance between each of the three quantified data sets and 
was determined to be less than 7%. 
Statistical Analysis 
 Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA 
and One-way ANOVA with Tukey post-hoc analysis was used to analyze within group 
data. Balb/c mice and Apcmin/+ mice were not compared. Western blot and histology data 
statistical analysis was calculated by Student's t-test using SigmaStat version 3.5 (Systat 
Software Inc., Richmond, CA). Results are reported as means ± standard error of the 
mean. Significance was set with an alpha value of p < 0.05. 
3.4 Results 
DCQ reduces tumor xenograft weight and area after 4 weeks of treatment in Balb/c mice. 
 We investigated the effectiveness of a 17 mg/kg DCQ dosage given semiweekly 
to Balb/c mice with CT-26 tumor xenografts. Figure 1A shows photographs of DMSO 
and DCQ treated mice at the beginning and after the 4 week treatment period After 4 
weeks of treatment, DCQ treated mice showed decreased tumor weight (p < 0.05) and 
area (p < 0.05) compared to DMSO treated mice (Figure 1 B-C). This data is consistent 
with the results obtained by where tumor volume was shown to be lower in DCQ treated 
Balb/c mice with MDA-MB-231 tumor xenografts (Ghattass, K, et. al., 2014). 
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DCQ induces tumor apoptosis and decreases proliferation. 
 Two important hallmarks of cancer that contribute to the malignancy of tumor 
development is the ability for the cancerous mass to resist apoptotic signaling and sustain 
proliferative signaling. An ideal chemotherapeutic drug would have the ability to induce 
both tumor cell apoptosis and block the tumor cells’ ability to proliferate. To evaluate the 
effect of DCQ on inducing tumor apoptosis, a standard TUNEL staining assay was 
performed on excised tumor xenograft sections (Figure 2a). Balb/c mice treated with 
DCQ showed a significantly greater percent apoptotic area within the tumor mass (p < 
0.05) compared to DMSO treated mice (Figure 2b). To assess the ability of DCQ to block 
the sustained proliferation of tumor masses, a standard BrdU staining assay was 
performed on tumor xenograft sections (Figure 3). Balb/c mice treated with DCQ also 
showed a decreased percent proliferative area within the tumor mass (p < 0.05) compared 
to DMSO treated mice (Figure 3b). 
DCQ decreases nuclear expression of HIF-1α transcription protein. 
 The structural design of DCQ is the key to the increased effectiveness of DNA 
synthesis inhibition. In the presence of an electron rich environment, a free radical 
intermediate is created by the transfer of an electron from this electron rich environment 
to the electron-poor nitrogen centers of the 1,4-di-N-oxide moiety. In a hypoxic 
environment, this transfer is more likely to occur due to the highly reducing conditions of 
hypoxic cells, leading to hypoxic cells acting as a targeting element to cytotoxicity of the 
compound, (Ke & Costa., 2006) this is especially true in models of colorectal cancer 
where tumors thrive in a low oxygen environment. To assess the extent of hypoxic 
signaling within the tumor xenografts, nuclear HIF-1α expression was evaluated via 
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Western blot analysis (Figure 4a). DCQ treated Balb/c mice decreased both HIF-1α 
(p<0.05) and undifferentiated HIF-1 (p<0.05) protein levels within the nucleus of the 
tumor cells (Figure 4b,c).   
DCQ induces tumor cell apoptosis through intracellular death pathway. 
 Gali-Muhtasib et al., 2005 showed DCQ was the most effective QdNO to induce 
tumor cell apoptosis in cultured T-84 human carcinoma cells and did so by increasing 
intracellular pro-apoptotic protein Bax while decreasing anti-apoptotic protein Bcl-2. To 
confirm activation of this pathway, we mapped the pro-apoptotic and anti-apoptotic 
markers of the intracellular death pathway in the excised tumor xenografts (Figure 5a) via 
Western blot analysis. In this circumstance, DCQ increased pro-apoptotic genes cleaved 
caspase-9 (p<0.05), dephosphorylated-Bad (p<0.001), and Bax (p<0.05) after 4 weeks of 
treatment (Figure 5b, c, d). DCQ decreased anti-apoptotic protein Bcl-2 (p<0.05), and 
this treatment effectively reducing the ratio of Bcl-2 to Bax (Figure 5e). Loading of 
equivalent amounts of protein for all samples was confirmed by ponceau stain. On the 
basis of quantification of the data by scanning densiometry, DCQ was found to increase 
intracellular death pathway signaling.  
4 weeks DCQ treatment at 17mg/kg may not induce liver, kidney, or brain apoptosis. 
 In an effort to test the safety of the determined maximal tolerated dose of 
17mg/kg, brain, liver, and kidney were excised from mice at the time of sacrifice and 
stained for apoptotic activity via standard TUNEL staining assay. Representative photos 
of DMSO and DCQ treated mice in Figure 6 show no positive indications of apoptotic 
activity in either mouse. These results indicate that DCQ treatment at 17mg/kg may not 
induce toxicity to these organs during the 4 week treatment period. 
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Improved clinical score after 4 weeks DCQ treatment in 16 week old Apcmin/+ mice 
After confirming the effectiveness and safety of the 17 mg/kg dosage in the tumor 
xenograft model, the effectiveness and safety of the same dosage in a genetic model of 
intestinal/colorectal cancer was determined. Apcmin/+ mice began semiweekly clinical 
evaluation (Table 1) at 8 weeks of age and began semiweekly DCQ or DMSO treatments 
at 16 weeks of age which lasted 4 weeks. Figure 8a represents the clinical score tallied 
across the entire study, statistical significance was only calculated from the beginning of 
the treatment period, 16 weeks of age. Although the breeding group used for the DCQ 
treatment showed a higher clinical score prior to treatment and had a significantly higher 
score at the first treatment visit (p < 0.05); by week 17, mice receiving DCQ treatment 
showed a continuous downward progression in clinical score which tallied to be 
significantly less than the DMSO treated mice (p < 0.05) at all but one time point (week 
16.5) throughout the treatment period.. Decreased clinical score was attributed to a 
decreased scoring in diarrhea and fecal hemoccult (data not shown). At 20 weeks of age, 
DCQ treated mice were determined to still be “healthy” by the Arnold School of Public 
Health animal facility staff and were given another week of treatment before sacrifice. 
DCQ treated mice were all sacrificed at 21 weeks of age. Clinical score data for DMSO 
treated mice was only tallied to 19 weeks of age due to decreased health of the animals 
and many needing to be sacrificed before reaching the 20 week threshold. The data point 
at 19 weeks of age for the DMSO treated group represents the last point which all mice 
within the DMSO treatment group clinical score was tallied. One-way ANOVA of 
Apcmin/+ mice within the DCQ treatment group revealed a progressive increase in clinical 
score relative to time from 8 weeks to 16 weeks of age (p < 0.001), prior to DCQ 
administration. From 16 weeks of age to sacrifice, during the DCQ treatment period, 
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mice showed significant decrease (p < 0.001) in clinical score relative to time which 
indicates a change in clinical score was induced by DCQ treatment. 
DCQ decreases intestinal tumor count and size 
 To investigate the overall effectiveness of DCQ, we excised the entire small 
intestine and colon and counted tumors after staining with 0.1% methylene blue. No 
morphological differences in the colon were observed between the DMSO and DCQ 
treated mice (Figure 8a). However, DCQ treated mice did show a decreased total tumor 
number (p < 0.001) and large tumor size (p < 0.001) compared to DMSO treated mice 
(Figure 8b,c). No differences were seen in small and medium tumor size between the two 
groups. 
DCQ induces colon tumor specific apoptosis while preserving normal colon epithelium 
We showed in the Balb/c mouse xenograft model that DCQ given at a 17 mg/kg 
dosage effectively increased tumor tissue apoptosis and decreased proliferation while not 
indicating toxicity to liver, kidney and brain tissue. (Figure 2, 3, and 6). To further 
elucidate the effectiveness and safety of DCQ, apoptosis and proliferation data was 
obtained in identified tumors of Apcmin/+ mice within the colon (Figure 9). Tissue sections 
were specifically cut to obtain a large amount of colon tissue in an effort to obtain the 
surrounding normal colon epithelium for analysis which would be also used to observe 
colon histopathology and any apoptotic activity occurring within the normal colon 
epithelium (Figure 10). Within the tumor, DCQ treated mice had significantly greater 
apoptotic activity (p < 0.001) and significantly lower proliferative activity (p < 0.05), 
these findings paralleling the finding in the Balb/c xenograft model. Observing the 
obtained TUNEL stain of the surrounding normal colon tissue, no increased apoptotic 
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activity was observed, indicating DCQ only induced apoptosis to the tumor tissue (Figure 
10). The WT TUNEL stain was performed as a negative control. 
DCQ targets HIF-1α pathway and induces intracellular death in colon tumors of Apcmin/+ 
mice 
 Functional cross-talk has been reported between HIF-1α and the Apc gene at the 
transcriptional level. Newton et. al., 2010 reported a consistent direct transcriptional 
repression of Apc by HIF-1α in multiple cell lines. HIF-1α when bound to a hypoxia-
responsive element, dubbed HRE, in the APC promoter region in the presence of 
hypoxia. Therefore, the Apcmin/+ model of colorectal cancer provided an interesting target 
for testing the effectiveness of DCQ on reducing the hypoxic signaling within the tumor 
tissue. Colon tumors excised from the DCQ treated Apcmin/+ mice showed nearly non-
detectable nuclear HIF-1α protein expression (p < 0.05) when compared to DMSO 
treated mice (Figure 11a, b).  
Along with these findings, we also saw an increased pro-apoptotic protein Bax (p 
< 0.05) and decreased anti-apoptotic protein Bcl-2 (p < 0.05) in DCQ treated mice 
compared to DMSO treated controls (Figure 12 a, b, c). Thus, effectively decreasing the 
Bcl-2 to Bax ratio within the tumor. These results were parallel to the data obtained from 
the Balb/c xenograft tumors. 
DCQ treated mice Apcmin/+mice experience less liver apoptosis and no indications of 
kidney or brain apoptosis 
 As was done with the Balb/c treated mice, we investigated the safety of the 17 
mg/kg DCQ dosage by TUNEL staining excised liver, kidney, and brain tissue from the 
treated Apcmin/+ mice. Similar to the Balb/c mice, no apoptosis was detected in the kidney 
or brain tissue of DMSO or DCQ treated mice (Figure 14 a). However, DCQ treated mice 
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showed a significantly lower (p < 0.01) amount of apoptotic cells compared to DMSO 
treated control mice (Figure 14 a,b). These results show less cell death was occurring in 
the livers of DCQ treated mice.  
3.5 Discussion 
 Despite advancements in cancer prevention and treatment methods the burden of 
colorectal cancer costs the United States over 51,000 lives and $12.2 billion dollars in 
2012 alone, $10.7 billion being due to lost productivity and premature death. Two of the 
most significant and most investigated hallmarks of cancer are the tumor’s ability to 
sustain an abnormally high level of proliferative signaling and to resist apoptotic 
signaling. A major contributor to these hallmarks is the chronic hypoxia present in the 
tumor environment which activates the HIF-1α pathway. This hypoxic response is 
especially true in the already hypoxic environment of the mammalian colon. 
Identification of this trait has led to drug engineering that is aimed at targeting the 
hypoxic environment as a method of directly utilizing the hypoxic regions of against the 
tumor. The current study was aimed at investigating the safety and effectiveness of the 
novel hypoxia targeting drug 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide 
(DCQ). We report the novel finding that the maximal tolerated dose of 17 mg/kg is both 
effective in inducing colorectal tumor cell apoptosis and blocking tumor cell proliferation 
in two models of colorectal cancer and is safe at current dosage by showing a lack of 
normal tissue death. This study also indicated DCQ is capable of reducing critical 
hypoxia signaling protein HIF-1α and leads to up-regulation of pro-apoptotic and 
reduction of anti-apoptotic genes involved in intracellular apoptosis signaling within the 
tumor.     
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 Previous investigations completed at the American University of Beirut have 
shown that DCQ is a hypoxia activated compound that is effective at inducing tumor 
specific apoptosis and also has increased effectiveness when supplemented with acute 
doses of radiation in-vitro (Diab‐Assef et al., 2002; El-Khatib et al., 2010; Gali-Muhtasib, 
Diab-Assaf, et al., 2004; Haykal et al., 2008, 2009; Itani et al., 2007). The most recent 
investigation completed at the American University of Beirut identified a maximal 
tolerated dosage in mice of 17 mg/kg in healthy mice (Ghattass et al., 2014). The next 
step in further progressing the understanding of DCQ was to design an investigation that 
would translate the compound’s ability to effectively reduce tumor burden in animals at a 
progressed stage of colorectal cancer. This study, therefore, was designed to evaluate two 
animal models of colorectal cancer which investigated the clinical safety and 
effectiveness in both a tumor xenograft model and a genetic model of colorectal cancer.  
 Balb/c implanted with CT-26 tumor xenografts given 4 weeks of a semiweekly 
17mg/kg DCQ treatment showed reduced tumor size and weight. Tumor tissue was 
stained for presence of apoptosis and proliferation, and the data indicate that tumors of 
DCQ treated mice had significantly greater apoptosis and lower proliferation compared to 
control mice. Similar results are reported for the 20 week old Apcmin/+ mice treated with 
the same 4 week semiweekly treatment plan as Balb/c mice. The two animal models, 
Balb/c implant mice and Apcmin/+ mice were not compared. DCQ treated Apcmin+ mice 
showed significantly lower clinical score after just one week of treatment and continued a 
downward trend in clinical score until time of sacrifice. The average life of an Apcmin/+ 
mouse is approximately 120 days or 18 weeks of age. DMSO treated control mice to 
survive just past 19 weeks of age but the life of all DCQ treated mice was extended to 21 
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weeks of age. The major factor of the reduction in clinical score was through the reduced 
diarrhea and fecal hemoccult scores, both significant clinical indications of advanced 
intestinal and colorectal cancer. Collectively, these results demonstrate that the 17 mg/kg 
dosage is effective in reducing tumor burden in both an implanted tumor model and a 
genetic model of intestinal and colorectal cancer. We would like to note that although 
tumor counting from the intestines of the Apcmin/+ mice showed a decreased total tumor 
count and large tumor size in DCQ treated mice, total number of tumors reported was 
noticeably lower than most previously reported studies involving Apcmin/+ mouse models 
(Balmain, Gray, & Ponder, 2003; Johnson & Fleet, 2013; Moser et al., 1990). 
 The data from this study provide evidence that DCQ treatment in Apcmin/+ mice 
induced tumor apoptosis and did not induce normal colon tissue death. Clinically, this 
finding is exciting because many drugs failing to accomplish this feat. This supports the 
previous findings by the group at the American University of Beirut that DCQ works in a 
tumor specific manner to induce only tumor cell apoptosis while preserving normal colon 
tissue. Protein analysis in tumors from both animal models indicate the down-regulation 
of nuclear transcription protein HIF-1α with DCQ treatment. The key moiety of the DCQ 
compound is at the 1,4-dioxide structure. In a hypoxic environment, electron transfer is 
more likely to occur to the 1,4-dioxide moiety due to the highly reducing conditions of 
the hypoxic cells, this allows a compound such as DCQ to utilize the hypoxic areas of 
tumors as a targeting element to the cytotoxicity of these compounds. A study by 
(Newton et. al, 2010)  provided evidence of functional cross-talk between HIF-1α and the 
Apc gene at the transcriptional level. This relationship was confirmed in an Apc depletion 
model which showed an increased HIF-1α expression and activity in tumor cells.  In the 
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present study, the nearly non-detectable HIF-1α protein expression in DCQ treated 
Apcmin/+ mice are an exciting find, this data indicating that DCQ has the ability to reduce 
critical nuclear transcription factor HIF-1α in the tumor environment in-vivo. However, 
we cannot suggest any specific mechanistic results without further mechanistic studies 
that would confirm the effectiveness of DCQ in reversing the increased hypoxia in 
tumors with Apc gene deletion.  
 Previously established is that the HIF-1α pathway, when highly expressed in a 
tumor environment, increases transcription of trophic factors such as VEGF, which can 
lead to the inhibition of intracellular apoptosis through phosphorylation of the PI-3kinase. 
Once activated, the PI-3kinase will ultimately lead to the phosphorylation of pro-
apoptotic protein Bad which increases the Bcl-2:Bax ratio and prevents cell apoptosis. An 
investigation by Gali-Muhtasib, Diab-Assaf, et al., 2004 at the American University of 
Beirut reported DCQ increased pro-apoptotic protein Bax and decreased anti-apoptotic 
protein Bcl-2 in multiple human cell lines. We have evidence that in-vivo this response is 
activated in the tumor cells of both a xenograft and genetic model of intestinal/ colorectal 
cancer after 4 weeks of semiweekly DCQ treatment at 17 mg/kg. This study serves as the 
translational step to the animal use of the drug and indicates DCQ induces tumor cell 
apoptosis by increasing intracellular expression of pro-apoptotic proteins and decreasing 
anti-apoptotic proteins and warrants further animal and mechanistic investigations to 
observe the complete anti-tumor mechanisms of DCQ. 
 Another interesting find was the decreased incidence of liver apoptosis in Apcmin/+ 
mice treated with DCQ. Liver toxicity and hypertrophy is a trademark trait of colorectal 
cancer progression and cancer cachexia (Narsale et al., 2015). The decreased liver 
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apoptosis suggests a decreased tumor burden as a result of DCQ treatment, however, the 
data does not indicate a direct relationship between DCQ and decreased liver apoptosis 
and warrants further investigations to observe if DCQ has a direct effect on preserving 
liver function. 
Conclusion 
 The involvement of hypoxia in the progression of colorectal cancer has led to the 
development of hypoxia targeting chemotherapeutics, however, none of which have 
shown to be safe and effective in eradicating colorectal tumors. In the present study, 
novel compound DCQ is shown as safe and effective in reducing tumor burden in 
xenograft and genetic models of colorectal cancer. DCQ, given semiweekly at 17 mg/kg 
for 4 weeks was effective at inducing tumor specific apoptosis and reducing tumor tissue 
proliferation while preserving normal colon tissue and without inducing apoptosis to vital 
organs. We also showed the down-regulation of critical hypoxia gene HIF-1α and the up-
regulation of pro-apoptotic gene paralleled by decreased anti-apoptotic genes involved in 
regulation of the intracellular apoptosis pathway within the tumors of both Balb/c and 
Apcmin/+ mice treated with DCQ. Additional experiments are needed to be performed to 
establish the complete understanding of the anti-tumor mechanisms of DCQ, and should 








Table 3.1 Apcmin/+ mouse clinical score guidelines. Clinical score was monitored on all 
ten Apcmin/+ mice from 8 weeks of age until sacrifice. Body weight loss was determined 
as percent (%) loss from 8 weeks of age. Fecal Hemoccult and diarrhea was evaluated 
during every clinical visit.  
Body Weight Loss Fecal Hemoccult Diarrhea 
5% = 0 No blood = 0 Hard Stool = 0 
6-10% = 1 Some blood = 2 Soft Stool = 2 
11-15% = 2 Severe bleeding = 4 Runny and soft = 4 
16-20% = 3   















3.6 Figure Legend 
Figure 3.1 Experimental Design. (A) At 10 weeks of age, sixteen Balb/c mice were 
randomly assigned to a DMSO (control) or DCQ treatment group and implanted with 2 x 
106 CT-26 cells. Tumors were allowed to grow for 2 weeks before receiving bi-weekly 
injections of either DMSO or DCQ over a 4 week period. (B) At 8 weeks of age, ten 
Apcmin/+mice were randomly assigned to a DMSO (control) or DCQ treatment group and 
began clinical evaluation. At 16 weeks of age, mice began receiving a bi-weekly injection 
of either DMSO or DCQ over a 4 week period. Clinical evaluations were taken bi-weekly 
through the course of the experiment. # = CT-26 tumor implantation, ** = Begin Apcmin/+ 
clinical evaluation, * = DMSO or 17mg/kg DCQ injection. 
Figure 3.2 DCQ therapy decreases tumor xenograft weight and area. Balb/c with 
flank tumor and final tumor weight and area. (A) Images of Balb/c mice with flank tumor 
at beginning of therapy (Day 1) and after 4 weeks (Day 28) of DMSO or DCQ injection. 
(B) Subcutaneous tumors removed and weighed at time of sacrifice in grams (g). (C) 
Final tumor area measured prior to sacrifice in millimeters squared (mm^2). Values are 
means ± standard error.  *p<0.05. 
Figure 3.3 DCQ increases apoptosis in tumor xenografts of Balb/c mice. Tumor 
Apoptosis: (A) TUNEL assay of tumor tissues imaged at 4x and 20x of DMSO and DCQ 
injected mice. (B) Percent total apoptotic area of tumor tissue. Arrows indicate examples 
of positively labeled cells. Values are means ± standard error. *p<0.05. 
Figure 3.4 DCQ decreases proliferation in tumor xenografts of Balb/c mice. Tumor 
Proliferation: (A) BrdU assay of tumor tissues imaged at 4x and 20x of DMSO and DCQ 
injected mice. (B) Percent total proliferative area of BrdU positive cells. Arrows indicate 
examples of positively labeled cells. Values are means ± standard error. *p<0.05. 
Figure 3.5 DCQ decreases nuclear HIF-1α protein expression in tumor xenografts of 
Balb/c mice.  (A) Nuclear expression of HIF-1α protein is decreased in mice given DCQ 
treatment compared to DMSO control. Quantification of HIF-1α (B) and HIF-1 (C) levels 
is shown as integrated optical density as determined by densiometry analysis. Values are 
means ± standard error. *p< 0.05. 
Figure 3.6 DCQ increases pro-apoptotic proteins Cleaved Caspase-9, 
Dephosphorylated-Bad, and Bax and decreases anti-apoptotic protein Bcl-2 in 
tumor xenografts of Balb/c Mice. (A) Cytoplasmic expression of Cleaved Caspase-9, 
Dephosphorylated-Bad (Dephos-Bad), and Bax pro-apoptotic proteins and anti-apoptotic 
protein Bcl-2 in DMSO and DCQ treated Balb/c mice. (B-E) Quantification of Cleaved-
Caspase-9, Dephos-Bad, Bax, and Bcl-2 is shown as integrated optical density as 
determined by densiometry analysis, respectively. Values are means ± standard error. * p 
< 0.05, # p < 0.001. 
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Figure 3.7 DCQ treatment may not induce liver, kidney, or brain apoptosis in Balb/c 
mice. Photographs of liver, kidney, and brain of Balb/c mice with CT-26 xenografts 
given DMSO or DCQ. Absence of brown labeled cells indicates no increased apoptosis in 
DCQ treated mice. 
Figure 3.8 DCQ improves Apcmin/+ mouse clinical score after 4 weeks of treatment. 
(A) Clinical scores for DMSO and DCQ treated Apcmim/+ mice during the 13 weeks of 
study. Weight loss, diarrhea and blood in stools were used as parameters to calculate the 
clinical score (Table 1). Statistical significance was only tested from 16 weeks of age to 
sacrifice between both treatment groups. (B) Photographs of mouse showing regressed 
rectal prolapse after 1 week of DCQ treatment. Values are means ± standard error. * p < 
0.05. 
Figure 3.9 DCQ reduces Apcmin/+ mouse intestinal tumor count and size. (A) 
Representative photographs of methylene blue-stained intestinal tissues for DMSO and 
DCQ treated Apcmin/+ mice. Difference in total poly number (B) and polyp size (C) were 
measured in Apcmin/+ treated with DMSO and DCQ. Values are means ± standard error. * 
p <0 .05. 
Figure 3.10 DCQ induces colon tumor apoptosis and decreases tumor proliferation 
of Apcmin/+ mice. TUNEL and BrdU assays were performed to observe and measure 
apoptotic activity and proliferative cells in identified colonic tumors of Apcmin/+ mice 
given DMSO and DCQ treatements. Average positively labeled apoptotic cells (A) and 
proliferating (B) cells in identified colonic tumors of DMSO and DCQ treated mice. (C) 
Representative photographs of TUNEL and BrdU assayed colonic tumors. Arrows 
indicate examples of positively labeled cells. Values are means ± standard error. *  p < 
0.05, # p < 0.001. 
Figure 3.11 DCQ does not induce normal colon epithelium apoptosis in Apcmin/+ 
mice. Identified normal colon tissue of WT, DMSO and DCQ treated mice was stained 
with hematoxylin and eosin and also observed for apoptosis via TUNEL assay. TUNEL 
assay WT representative was treated as a negative control. 
Figure 3.12 DCQ decreases nuclear expression of HIF-1α in colon tumors of Apcmin/+ 
mice. (A) Nuclear expression of HIF-1α protein is decreased in mice given DCQ 
treatment compared to DMSO control. (B) Quantification of HIF-1α levels is shown as 
integrated optical density as determined by densiometry analysis. Values are means ± 
standard error. * p < 0.05. 
Figure 3.13 DCQ increases pro-apoptotic proteins Cleaved Caspase-9 and Bax and 
decreases anti-apoptotic protein Bcl-2 in colon tumors Apcmin/+ mice. (A) 
Cytoplasmic expression of Bax pro-apoptotic protein and anti-apoptotic protein Bcl-2 in 
DMSO and DCQ treated Balb/c mice. Quantification of Bax (B) and Bcl-2 (C) is shown 
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as integrated optical density as determined by densiometry analysis, respectively. Values 
are means ± standard error. * p < 0.05. 
Figure 3.14 DCQ treatment decreases liver apoptosis and does not induce kidney or 
brain tissue apoptosis in Apcmin/+ mice. (A) Photographs of liver, kidney, and brain of 
Apcmin/+ mice treated with DMSO or DCQ. A decreased amount of apoptotic cells in the 
liver was noticed indicating less apoptosis and liver toxicity in DCQ treated mice. Arrows 
indicate examples of positively labeled cells. (B) Average positively labeled apoptotic 
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Figure 3.5 DCQ decreases nuclear HIF-1α protein expression in tumor xenografts of 













































































             
Figure 3.6 DCQ increases pro-apoptotic proteins Cleaved Caspase-9, 
Dephosphorylated-Bad, and Bax and decreases anti-apoptotic protein Bcl-2 in 



































































































































































































































Figure 3.10 DCQ induces colon tumor apoptosis and decreases tumor proliferation 
of Apcmin/+ mice. 
 
Figure 3.11 DCQ induces tumor specific apoptosis and decreases tumor 






































































Figure 3.13 DCQ increases pro-apoptotic protein Bax and decreases anti-apoptotic 












































































































Figure 3.14 DCQ treatment decreases liver apoptosis and does not induce kidney or 
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Specific Aim #1 will evaluate the safety and effectiveness of the 17mg/kg DCQ 
dosage in a xenograft and genetic model of colorectal cancer. 
 Rationale: It has been previously shown that DCQ is effective in causing tumor 
specific apoptosis and can repress tumor growth in multiple human cancer cell lines 
through activation mechanisms involving down-regulation of HIF-1α pathway (Diab-
Assef et al., 2002; El-Khatib et al., 2010; H. U. Gali-Muhtasib et al., 2005; Ghattass et 
al., 2014; Haykal et al., 2008, 2009). Toxicity studies from the American University of 
Beirut have suggested a concentration of 17mg/kg dose will be effective in causing tumor 
cell apoptosis while staying below systemic toxic levels, therefore preserving essential 
healthy tissue in both the GI system and the entire body. The 17mg/kg dosage has 
previously been shown to be effective in a breast cancer xenograft study however DCQ 
has yet to be investigated in-vivo for clinical effectiveness in a colorectal cancer model 
(Ghattass et al., 2014). Thus, we would like to investigate the safety and clinical 
effectiveness of the 17mg/kg dose in a tumor implant and genetic model of colorectal 
cancer. 
Experimental design for specific aim #1. Experiment 1 will determine the safety and 
clinical effectiveness of DCQ in 10 week old Balb/c mice implanted with CT-26 murine 
colorectal tumor cells and in 16 week old Apcmin/+ mice.  
 At approximately 10 weeks of age, Balb/c mice will be randomized to a control 
group or treatment group. 2 million CT-26 cells, kindly provided by Dr. Marj Pena, were 
injected subcutaneously into the right flank of each mouse and allowed to grow for 2 
weeks. After 2 weeks DCQ will be dissolved in DMSO to create a 17mg/kg 
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concentration in a 100μL dose and injected twice a week for four weeks. Control mice 
will receive a 100μL injection of sterile DMSO twice a week for four weeks. At 10 weeks 
of age, Balb/c mice will be approximately 20g and will be able to withstand the tumor 
burden and chemotherapy treatments. Apcmin/+ mice were aged to 8 weeks of age and 
randomized into control and treatment groups. Twice a week, clinical evaluations will be 
conducted to measure body weight, food and water consumption, fecal hemoccult and 
diarrhea, and a description of any abnormal behavior or side effects that might be arising 
as part of the therapy. At 16 weeks of age, mice in their respective groups will receive a 
bi weekly 100μL injection of either DMSO or 17mg/kg of DCQ. Min mice have initiated 
body weight loss and intestinal polyp development and show a near maximum clinical 
score by 15-16 weeks of age, making it an ideal time point to assess the effectiveness of 
DCQ on the treatment of colorectal cancer. All mice will be housed in standard cages for 
the duration of the study. Body weight and tumor dimensions in Balb/c mice and clinical 
score in Apcmin/+ mice will be measured at the time of each treatment period and at the 
time of sacrifice. At sacrifice, brain, liver, kidney, spleen, and plasma will be collected 
from all mice, tumor xenografts will also be taken from Balb/c mice, and colon and small 
intestine will also be collected from Apcmin/+ mice. Sections of tumor xenografts, brain, 
liver, kidney, colon, and small intestine from respective mice will be fixed in 10% 
formalin for 24 hours, preserved in 70% ethanol, and then embedded in paraffin wax to 
be sectioned for immunohistochemistry. All tissues extracted will also be weighted and 
frozen for protein analysis.  
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Experiment #1 will determine the safety and effectiveness of DCQ in a tumor xenograft 
and genetic animal model of colorectal cancer. 
Animals: Balb/c male mice will be bred with female Balb/c mine in the USC Discovery 
building Arnold School of Public Health animal resource facility. All mice will be 
provided with standard rodent chow (Harlan Teklad Rodent Diet, #8604, Madison, WI) 
and water ad libitum. Body weights will be measured throughout the course of the study. 
At 10 weeks of age, mice will be injected by a member of Dr. Marj Pena's lab with 2 
million cultured CT-26 murine colorectal cancer cells each and assigned into one of two 
groups; control or DCQ treatment. Apcmin/+ male mice on a C57BL/6 background will be 
bred with female C57BL/6 mice in the Discovery building Arnold School of Public 
Health animal resource facility. Animals will be genotyped as heterozygous for the Apc 
gene. All mice will be provided with standard rodent chow (Harlan Teklad Rodent Diet, 
#8604, Madison, WI) and water ad libitum. All mice will undergo clinical evaluation and 
receive clinical scores based on the protocol and guidelines of the Fayad lab. At 8 weeks 
of age, mice will be assigned to one of two groups; control or DCQ treatment. DCQ was 
synthesized from 5,6-dichlorobenzofurazan oxide and dibenzoylmethane via the Beirut 
reaction by Dr. Makhluf J. Haddadin and provided by Dr. Hala Gali-Muhtasib (American 
University of Beirut, Beirut, Lebanon). After two weeks of tumor growth, Balb/c mice 
will begin a bi-weekly treatment period. DCQ treatment will consist of a bi-weekly 
100μL intraperitoneal injection of DCQ dissolved in DMSO at a concentration of 
17mg/kg body weight. Balb/c control mice will receive a bi-weekly vehicle injection of 
100μL of DMSO. Balb/c mice will be sacrificed at 16 weeks of age after 4 weeks of 
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treatment. At 16 weeks of age, Apcmin/+ mice will receive either a bi-weekly 
intraperitoneal 100μL injection of DMSO or DCQ at a concentration of 17mg/kg body 
weight. All mice will be sacrificed at 20 weeks of age after a 4 week treatment period.  
Based on previous drug development preliminary studies and on animal data from our 
lab, 5-6 mice per group are sufficient to detect a difference in clinical and experimental 
data. 
Table A.1 Animal treatment groups for experiment #1. 
Strain Treatment 

























Table A.2 Animal clinical score guidelines 
Body Weight Loss Fecal Hemoccult Diarrhea 
5% = 0 
6-10% = 1 
11-15% = 2 
16-20% = 3 
>20% = 4 
No blood = 0 
Some blood = 1 
Sever bleeding = 2 
Hard Stool = 0 
Soft stool = 1 




Tumor size and weight: 
Tumor size will be evaluated at each treatment period in Balb/c mice. At sacrifice, tumor 
will be removed from the mice and weighed. 
Clinical Score: 
Clinical score in Apcmin/+ mice will be evaluated from 8 weeks of age through time of 
sacrifice.      
Systemic toxicity: Brain, liver, and kidney will be analyzed for presence of apoptosis via 
TUNEL assay. Serum levels of IL-6 will be assessed via ELISA also to determine 
relative levels of systemic inflammation. 
Secondary outcomes: 
Body composition: DEXA scan will be performed on each mouse prior to sacrifice and 
be used to determine between group differences in body composition after 4 weeks of 
therapy. 
Specific Methodology Aim #1: 
Animals: Balb/c male mice will be bred with female Balb/c mice in the Discovery 
building Arnold School of Public Health animal resource facility. Apcmin/+ male mice on a 
C57BL/6 background will be bred with female C57BL/6 mice in the Discovery building 
Arnold School of Public Health animal resource facility. Resulting heterozygous mice 
from the Apcmin/+ cross will develop intestinal and colonic tumors as early as 8 weeks of 
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age and typically have a life span of 20-22 weeks of age. All animals will be housed in 
standard cages and the room will be maintained on a 12:12 light:dark cycle with the light 
period starting at 0700. Mice will be provided with standard rodent chow (Harlan Teklad 
Rodent Diet #8604) and water ad libitum. Body weight and tumor size will be monitored 
during the course of the study, final tumor weight will be measured at time of sacrifice. 
All animals at time of sacrifice will be injected with 1mg of BRDU dissolved in 
phosphate buffered saline (PBS) and undergo DEXA scan prior to blood draw and 
cervical dislocation. All animal experimentation is approved by the University of South 
Carolina's Institutional Animal Care and Use Committee. Tumor growth will be allowed 
to occur for 2 weeks until treatment periods will begin. At this point, DCQ will be 
prepared in DMSO so as to obtain a concentration of 17mg/kg in a 100μl injection 
normalized to the average weight of the mice. 
Genotyping: All animals from the Apcmin/+ cross will be genotyped using a tail snip. At 4-
5 weeks of age; animals will be weaned, numbered, and a small tail snip (~1-2mm) 
collected. The tail snip is digested in 200μL of tail digest buffer and 5μL of proteinase K. 
Tails are incubated overnight in a water bath set at 55OC. After incubation, samples are 
heat shocked at 95OC in a dri-bath for 10 minutes. Heterozygosity of the Apc gene will be 
determined via a PCR reaction (Apc forward 5' TGAGAAAGACAGAAGTTA 3', reverse 
5' TTCCACTTTGGCATAAGGC 3'). PCR products are run out on a 5% polyacrylamide 
gel and exposed to UV light. Presence of a band indicates heterozygosity of the Apc gene.  
Tissue Collection: Mice will be anesthetized via exposure to an isofluorane and oxygen 
mixture. Blood will be collected from the retro-orbital sinus using a capillary tube. Blood 
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will be spun at 4OC, 10,000rpm, for 10 minutes. Plasma will then be pipetted off and 
stored at -80OC until analysis. Brain (br), liver (l), kidney (k), spleen (sp), and tumor 
xenografts (tmr) from Balb/c mice will be excised, rinsed in PBS, frozen in a dry ice box, 
and stored at -80OC until further analysis. Parts of each tissue will also be fixed in 10% 
formalin for 24 hours, preserved in 70% ethanol, and then embedded in paraffin wax for 
histological sectioning. Small intestine, and colon from the Apcmin/+ mice will be chosen 
for sections containing tumors will be fixed in 10% formalin for 24hours, preserved in 
70% ethanol, and then embedded in paraffin wax for histological sectioning, brain (br), 
liver (l), kidney (k), spleen (sp) will also be collected. Parts of each tissue will also be 
excised, rinsed in PBS, frozen in a dry ice box, and stored at -800C until further analysis. 
Remaining sections of the small intestine will be rinsed with PBS and opened 
longitudinally. Sections will be fixed in 10% formalin for 24 hours and then preserved in 
70% ethanol and used for intestinal tumor counts in the Apcmin/+ mice.  
Polyp count: Intestinal polyps will be counted by staining in methylene blue. Formalin 
fixed intestinal sections from all Apcmin/+ mice were rinsed in deionized water, briefly 
stained in 0.1 % methylene blue, and counted by the same investigator who was blinded 
to the treatments. Polyps were counted under a dissecting microscope, using forceps to 
pick through the intestinal villi and identify polyps. Polyps were categorized as ≥ 1 mm 
or < 1mm in the small intestine and > 2 mm, 1-2 mm, and < 1 mm in the large intestine. 
After polyps were counted, intestinal sections were placed in 70 % ethanol for further 
analysis. Pilot data yielded an interassay coefficient of variation of 4 %. 
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Plasma IL-6: Plasma IL-6 will be measured using a mouse specific ELISA kit. 
Approximately 25-50μL of plasma will be incubated. A standard curve will be used to 
determine the levels of circulating IL-6 in all samples after treatment with DCQ or 
DMSO. An ELISA plate will be coated with capture antibody using a coating buffer and 
set to incubate in 4OC overnight. After washing the plate 100μL of blocking solution is 
added for 1 hour. After three washes, 100μL of standard or diluted sample is added to the 
wells in duplicate and incubated for 1hr. After 7 washes, 100μL of TMB cocktail is added 
to each well and stored in the dark for 30 minutes. 50μL of Stop solution is added to the 
wells and the plate is read at 450nm and 570nm according to the manufacturer's 
instructions. 
Hematoxylin and Eosin Staining (H&E): Transverse sections (~5μm) will be cut from the 
paraffin embedded kidney and liver of Balb/c and Apcmin/+  mice on a rotary microtome. 
Cut tissues will be allowed to expand on a 400C -450C water bath and then attached to (+) 
charged saline coated microscope slides. Excess paraffin is removed by placing slides in 
a 650C oven for 1hr and then stored at 40C until staining. Sections will be warmed to 
room temperature for 5-10minutes. Tissue morphology will be analyzed by observation 
and comparison to healthy tissue control sections. Sections are deparaffinized using the 
following washing progression; 3x5min xylene washes, 2x5min 100% EtOH, 1x3min 
95% EtOH, and 1x3min 70% EtOH. Sections are then washed for 5min in dH2O, stained 
with filtered hematoxylin for 5min, then again washed 6x5 in dH2O. Sections are washed 
in acid alcohol mix (160mL 100% EtOH, 1mL acetic acid, and volumed to 200mL with 
dH2O) for 6 dips then again washed in dH2O for 4 dips. Sections are then washed in 
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Ammonia H2O (0.6mL Ammonium OH volumed to 200mL with dH2O) for 6 dips and 
then again washed in dH2O for 10min. The sections will then be stained with Eosin for 
3min and dehydrated in the following alcohol progression; 1x2min 70% EtOH, 1x2min 
95% EtOH, 2x3min 100% EtOH, and 2x5min xylene. Sections are allowed to air dry for 
30min and then mounted for viewing with Permount mounting media. Digital 
photographs will be taken from each section at a 4x, 20x and 40x with a Nikon E600 
Widefield Epifluorescence and Darkfield Microscopy System at the University of South 
Carolina School of Medicine, and morphology examined.                   
TUNEL Assay: Transverse sections (~5μm) will be cut from the paraffin embedded 
brain, kidney, and liver of Balb/c and Apcmin/+  mice on a rotary microtome. Cut tissues 
will be allowed to expand on a 400C -450C water bath and then attached to (+) charged 
saline coated microscope slides. Excess paraffin is removed by placing slides in a 650C 
oven for 1hr and then stored at 40C until staining. Refrigerated sections will be warmed to 
room temperature for 5-10minutes. Sections will be stained for apoptotic tissue using 
Apop-Tag kit from Millipore (S7100). Sections are deparaffinized using the following 
washing progression; 3x5min xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH, 
and 1x3min 70% EtOH. Sections are then washed for 5min in 1X PBS and covered in 
20μg/ml proteinase K diluted from stock in fresh 1X PBS for 15min to remove any 
possible contaminants and inactivate nucleases that would degrade apoptotic tissue. After 
a 2x2min wash in dH2O the sections are blocked in 3% H2O2 for 5min at room 
temperature. After blocking the sections are washed 2x5min in PBS and incubated for 
2.5hrs in a humidified chamber in a working solution of TdT enzyme at 370C. Enzymatic 
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reaction is stopped using a working strength stop solution for 10min and then washed for 
3min in PBS. Anti-dioxigenin conjugate is then applied to each section and incubated for 
30min at room temperature in a humidified chamber. After incubation sections are 
washed 4x2min in PBS and detection reagent DAB is applied to develop the desired 
intensity of potentially positive cells. After washing in 3x1min and 1x5min dH2O, slides 
are counterstained for 30sec with 5% methyl green and washed in dH2O until 
counterstain no longer fades. Slides are then mounted for viewing with Permount 
mounting media after a minimum 3hr drying period. Digital photographs will be taken 
from each section at a 4x, 20x and 40x with a Nikon E600 Widefield Epifluorescence and 
Darkfield Microscopy System at the University of South Carolina School of Medicine, 
and percent apoptotic tissue will be determined with imaging software (ImageJ, 
Bethesda, MD).  
Specific Aim #2: will determine the mechanism of action of DCQ in the two animal 
models of colorectal cancer. 
 Rationale: Studies in multiple human cell lines from the American University of 
Beirut have shown consistent results of increased mitochondrial induced apoptosis with 
DCQ treatment. The CT-26 xenograft and Apcmin/+ transgenic mouse are common 
experimental models of colorectal cancer. The mutated Apc gene causes activation of the 
Wnt/β-catenin pathway which is responsible for tumorgenesis in the colon and small 
intestines (Bienz & Clevers, 2000; Leclerc et al., 2004; Newton et al., 2010; Näthke & 
Rocha, 2011). Although this is a specific genetic model of cancer there is genetic 
variability in the tumor formation and therefore each tumor site is expected to respond 
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differently to drug treatment. HIF-1α and the Apc gene have been shown to have cross-
communication at the transcriptional level which serves as a driving force for intestinal 
tumorgenesis (Mehl et al., 2005; Newton et al., 2010; Yamulla et al., 2014). Since it has 
been determined that DCQ works through interruption of the HIF-1α pathway, we are 
interested in mechanistic differences between and within the murine CT-26 tumor 
xenograft model and Apcmin/+ genetic model of colorectal cancer. 
Experimental design for specific aim #2. Experiment 2 will evaluate the mechanism of 
action of DCQ inducing tumor specific apoptosis in a xenograft and genetic model of 
colorectal cancer. 
The same mice from Aim #1 will be used for Aim #2. At approximately 10 weeks of age, 
Balb/c mice will be randomized to a control group or treatment group. 2 million CT-26 
cells, kindly provided by Dr. Marj Pena, were injected subcutaneously into the right flank 
of each mouse and allowed to grow for 2 weeks. After 2 weeks DCQ will be dissolved in 
DMSO to create a 17mg/kg concentration in a 100μL dose and injected twice a week for 
four weeks. Control mice will receive a 100μL injection of sterile DMSO twice a week 
for four weeks. At 10 weeks of age, Balb/c mice will be approximately 20g and will be 
able to withstand the tumor burden and chemotherapy treatments. Apcmin/+ mice were 
aged to 8 weeks of age and randomized into control and treatment groups. Twice a week, 
clinical evaluations will be conducted to measure body weight, food and water 
consumption, fecal hemoccult and diarrhea, and a description of any abnormal behavior 
or side effects that might be arising as part of the therapy. At 16 weeks of age, mice in 
their respective groups will receive a bi weekly 100μL injection of either DMSO or 
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17mg/kg of DCQ. Min mice have initiated body weight loss and intestinal polyp 
development and show a near maximum clinical score by 15-16 weeks of age, making it 
an ideal time point to assess the effectiveness of DCQ on the treatment of colorectal 
cancer. All mice will be housed in standard cages for the duration of the study. Body 
weight and tumor dimensions in Balb/c mice and clinical score in Apcmin/+ mice will be 
measured at the time of each treatment period and at the time of sacrifice. At sacrifice, 
brain, liver, kidney, spleen, and plasma will be collected from all mice, tumor xenografts 
will also be taken from Balb/c mice, and colon and small intestine will also be collected 
from Apcmin/+ mice. Sections of tumor xenografts, brain, liver, kidney, colon, and small 
intestine from respective mice will be fixed in 10% formalin for 24 hours, preserved in 
70% ethanol, and then embedded in paraffin wax to be sectioned for 
immunohistochemistry. All tissues extracted will also be weighted and frozen for tissue 
analysis of hypoxia markers and intracellular apoptosis markers.  
Experiment #2 will determine the mechanism of action of DCQ in two animal models of 
colorectal cancer. 
Animals: The same mice from Aim #1 will be used in Aim #2. Balb/c male mice will be 
bred with female Balb/c mine in the USC Discovery building Arnold School of Public 
Health animal resource facility. All mice will be provided with standard rodent chow 
(Harlan Teklad Rodent Diet, #8604, Madison, WI) and water ad libitum. Body weights 
will be measured throughout the course of the study. At 10 weeks of age, mice will be 
injected by a member of Dr. Marj Pena's lab with 2 million cultured CT-26 murine 
colorectal cancer cells each and assigned into one of two groups; control or DCQ 
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treatment. Apcmin/+ male mice on a C57BL/6 background will be bred with female 
C57BL/6 mice in the Discovery building Arnold School of Public Health animal resource 
facility. Animals will be genotyped as heterozygous for the Apc gene. All mice will be 
provided with standard rodent chow (Harlan Teklad Rodent Diet, #8604, Madison, WI) 
and water ad libitum. All mice will undergo clinical evaluation and receive clinical scores 
based on the protocol and guidelines of the Fayad lab. At 8 weeks of age, mice will be 
assigned to one of two groups; control or DCQ treatment. DCQ was synthesized from 
5,6-dichlorobenzofurazan oxide and dibenzoylmethane via the Beirut reaction by Dr. 
Makhluf J. Haddadin and provided by Dr. Hala Gali-Muhtasib (American University of 
Beirut, Beirut, Lebanon). After two weeks of tumor growth, Balb/c mice will begin a bi-
weekly treatment period. DCQ treatment will consist of a bi-weekly 100μL 
intraperitoneal injection of DCQ dissolved in DMSO at a concentration of 17mg/kg body 
weight. Balb/c control mice will receive a bi-weekly vehicle injection of 100μL of 
DMSO. Balb/c mice will be sacrificed at 16 weeks of age after 4 weeks of treatment. At 
16 weeks of age, Apcmin/+ mice will receive either a bi-weekly intraperitoneal 100μL 
injection of DMSO or DCQ at a concentration of 17mg/kg body weight. All mice will be 
sacrificed at 20 weeks of age after a 4 week treatment period.  Based on previous drug 
development preliminary studies and on animal data from our lab, 5-6 mice per group are 









Activation of DCQ through HIF-1α pathway: 
The chemical structure of 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide is 
activated into a free radical intermediate in an electron rich environment. In a hypoxic 
environment, this transfer is more likely to occur due to the highly reducing conditions of 
hypoxic cells, leading to hypoxic cells acting as a targeting element to the cytotoxicity of 
these compounds. Presence of hypoxia inducible factor-1 alpha (HIF-1α) indicates 
vasculogenesis and angiogenesis of proliferating cells, a common characteristic of tumor 
cells. Intra-tumoral HIF-1α expression will be measured using western blot analysis of 
nuclear extracts to determine the level of environmental hypoxia present in the tumors 
found in the intestinal and colonic region. 
Presence of apoptosis and decreased proliferation: 
TUNEL and BRDU staining of xenograft tumors, small intestines, and colon tissue will 
be used to analyze the percentage of apoptotic tissue and decreased proliferation. This 
Table A.3 Animal treatment groups for experiment #2. 
Strain Treatment 




















will also allow for analysis of tumor region specificity of DCQ via analysis of healthy 
tissue surrounding small-intestine and colon tumors. 
Intracellular apoptosis:  
Mapping of the intracellular pro-apoptotic and anti-apoptotic genes will be measured 
using western blot analysis of cytoplasmic extracts of dephosphorylated-Bad, Bcl-2, Bax, 
and cleaved caspase-9. 
Secondary Outcomes: 
Point of Infiltration: Hematoxylin and Eosin (H&E) staining will be performed on liver 
and kidney tissue sections from each animal model to determine point of infiltration of 
metastatic tumors. 
Specific Methodology Aim #2 
Animals:  The same mice from Aim #1 will be used for Aim #2. Balb/c male mice will be 
bred with female Balb/c mice in the Discovery building Arnold School of Public Health 
animal resource facility. Apcmin/+ male mice on a C57BL/6 background will be bred with 
female C57BL/6 mice in the Discovery building Arnold School of Public Health animal 
resource facility. Resulting heterozygous mice from the Apcmin/+ cross will develop 
intestinal and colonic tumors as early as 8 weeks of age and typically have a life span of 
20-22 weeks of age. All animals will be housed in standard cages and the room will be 
maintained on a 12:12 light:dark cycle with the light period starting at 0700. Mice will be 
provided with ad libitum and standard rodent chow (Harlan Teklad Rodent Diet #8604). 
Food and water consumption in addition to body weight and clinical score will be 
monitored during the course of the study for the Apcmin/+ mice. All animals at time of 
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sacrifice are injected with 1mg of BRDU dissolved in phosphate buffered saline (PBS) 
and undergo DEXA scan prior to blood draw and cervical dislocation. All animal 
experimentation is approved by the University of South Carolina's Institutional Animal 
Care and Use Committee. Average mouse weight will be recorded through the first 8 
weeks of clinical evaluations (up to 16 weeks of age). At this point, DCQ will be 
prepared in DMSO so as to obtain a concentration of 17mg/kg in a 100μl injection 
normalized to the average weight of the mice. 
Tissue Collection: Mice will be anesthetized via exposure to an isofluorane and oxygen 
mixture. Blood will be collected from the retro-orbital sinus using a capillary tube. Blood 
will be spun at 4OC, 10,000rpm, for 10 minutes. Plasma will then be pipetted off and 
stored at -80OC until analysis. Brain (br), liver (l), kidney (k), spleen (sp), and tumor 
xenografts (tmr) from Balb/c mice will be excised, rinsed in PBS, frozen in a dry ice box, 
and stored at -80OC until further analysis. Parts of each tissue will also be fixed in 10% 
formalin for 24 hours, preserved in 70% ethanol, and then embedded in paraffin wax for 
histological sectioning. Small intestine, and colon from the Apcmin/+ mice will be chosen 
for sections containing tumors will be fixed in 10% formalin for 24hours, preserved in 
70% ethanol, and then embedded in paraffin wax for histological sectioning, brain (br), 
liver (l), kidney (k), spleen (sp) will also be collected. Parts of each tissue will also be 
excised, rinsed in PBS, frozen in a dry ice box, and stored at -800C until further analysis. 
Remaining sections of the small intestine will be rinsed with PBS and opened 
longitudinally. Sections will be fixed in 10% formalin for 24 hours and then preserved in 
70% ethanol and used for intestinal tumor counts in the Apcmin/+ mice. 
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Protein Extraction: Tumor xenografts from Balb/c mice and tumor containing colon 
tissue from Apcmin/+ mice will be weighted and homogenized using a dounce 
homogenizer. A nuclear extraction kit (ab113474) will be used to homogenize samples 
and separate nuclear and cytoplasmic extracts. Samples were weighted between 35 and 
45 mg. 5mL diluted ENE1 buffer and 5μL DTT was added to each sample for every gram 
on tissue weighted. Once grinded, samples were incubated on ice for 15 minutes and 
centrifuged for 10min at 12,000rpm at 4OC. The resulting supernatant was aliquoted as 
the cytoplasmic extract and the pellet was kept for nuclear extract. 10μL of 1:1000 
diluted DTT in ENE2 and PIC in ENE2 buffer was added to the nuclear pellet for every 
2mg of tissue and incubated on ice for 15min with 5sec cortex every 3min. After 
incubation, samples were centrifuged for 10min at 14,000rpm at 4OC and resulting 
supernatant was aliquoted as nuclear extract. Protein content is determined using the 
Bradford Assay (Bradford, 1976). 
Western Blot: Nuclear and cytoplasmic protein extracts will be separated by SDS-PAGE 
and transferred to nitrocellulose membranes. Bax, Bcl-2, Cleaved caspase-9, 
dephosphorylated-Bad, and HIF-1α (nuclear) will be probed for. Tissue homogenates, 
60μg for cytoplasmic and 10μg for nuclear, are separated on 10% to 15% SDS-
polyacrylamide gels. The gels are transferred to nitrocellulose membranes in 3hrs at 
220mA in cold transfer buffer with the transfer apparatus kept in a 40C refrigerator. After 
transfer, membranes are washed with dH2Ο and stained with ponceau S to ensure equal 
loading and proper transfer. Membranes are blocked in 5% PBS with 0.1% Tween 20 
(PBST) milk for 1hr at room temperature and placed in primary antibody at dilutions of 
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1:500 to 1:1000 in 5% PBST milk overnight to 72hrs at 40C, HIF-1α requires a 2.5 hour 
primary antibody incubation at room temperature. Secondary anti-rabbit IgG-conjugated 
secondary antibodies are incubated with the membranes at 1:2000 for 1hr in 5% PBST 
milk at room temperature. Enhanced chemiluminescence is used to visualize the 
antibody-antigen interactions and develop the blot using the SYNGENE G:BOX Chemi 
XX6. Digitally developed blots are analyzed by measuring the integrated optical density 
(IOD) of each band using digital imaging software (GeneTools from Syngene, 
Cambridge, UK). 
Hematoxylin and Eosin Staining (H&E): Transverse sections (~5μm) will be cut from the 
paraffin embedded small intestine and colon from the Apcmin/+mice on a rotary 
microtome. Cut tissues will be allowed to expand on a 400C -450C water bath and then 
attached to (+) charged saline coated microscope slides. Excess paraffin is removed by 
placing slides in a 650C oven for 1hr and then stored at 40C until staining. Sections will 
be warmed to room temperature for 5-10minutes. Sections will be stained for 
morphological analysis using the H&E staining protocol as describe in Aim 1. 
TUNEL Assay: Transverse sections (~5μm) will be cut from the paraffin embedded 
tumor xenografts, brain, kidney, and liver of Balb/c mice on a rotary microtome. Cut 
tissues will be allowed to expand on a 400C -450C water bath and then attached to (+) 
charged saline coated microscope slides. Excess paraffin is removed by placing slides in 
a 650C oven for 1hr and then stored at 40C until staining. Refrigerated sections will be 
warmed to room temperature for 5-10minutes. Sections will be stained for apoptotic 
tissue using Apop-Tag kit from Millipore (S7100) as described in Aim 1. 
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BrdU Staining: Transverse sections (~5μm) will be cut from the paraffin embedded brain, 
kidney, and liver of Balb/c mice on a rotary microtome. Cut tissues will be allowed to 
expand on a 400C -450C water bath and then attached to (+) charged saline coated 
microscope slides. Excess paraffin is removed by placing slides in a 650C oven for 1hr 
and then stored at 40C until staining. Sections will be warmed to room temperature for 5-
10minutes. Sections will be stained for proliferating tissue by tagging of BrdU present in 
actively dividing tissue using BRDU IN-SITU Detection Kit from BD Pharmingen 
(550803). Sections are deparaffinized using the following washing progression; 3x5min 
xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH, and 1x3min 70% EtOH. 
Sections are then washed for 5min in 1X PBS, blocked with 3% H2O2 for 10 minutes at 
room temperature, and then washed again 3x5min in PBS. Antigen retrieval is performed 
by preparing working solution of retrieval agents from the kit and autoclaving sections in 
the Liquid 20 cycle in the Public Health Research Center autoclave. After antigen 
retrieval, sections are cooled for 20 min and washed 3x5 min in 1X PBS. Primary 
antibody is prepared in a 1:10 dilution with diluent buffer and sections are incubated with 
primary antibody for 90 min in a humid chamber at 37 0C. After primary antibody 
incubation, sections are washed 3x2 min in 1X PBS and then covered with RTU 
Streptavidin-HRP secondary antibody and incubated for 30min in a humid chamber at 
room temperature. After incubation sections are washed 4x2min in PBS and detection 
reagent DAB is applied to develop the desired intensity of potentially positive cells. After 
washing in 3x1min and 1x5 min dH2O, slides are counterstained for 30 sec with 5 % 
methyl green and washed in dH2O until counterstain no longer fades. Slides are then 
mounted for viewing with Permount mounting media after a minimum 3 hr drying period. 
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Digital photographs will be taken from each section at a 4x, 20x and 40x with a Nikon 
E600 Widefield Epifluorescence and Darkfield Microscopy System at the University of 
South Carolina School of Medicine, and percent apoptotic tissue will be determined with 
imaging software (ImageJ, Bethesda, MD). 
 
